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Abstract
The goal of the research presented in this dissertation is to develop novel water soluble
carboranylporphyrins that can deliver therapeutic dosage of boron specifically to tumors
for application in boron neutron capture therapy. In order to accomplish this goal novel
water soluble tetra(nido-carboranyl)porphyrin and the octa(nido-carboranyl)porphyrin
with high boron contents are synthesized by the condensation of the carborane substituted
benzaldehyde with the pyrrole under acidic conditions. These porphyrins are made water
soluble by the deboronation of the closo-carboranes to afford the corresponding
amphiphilic nido-carborane cages. The low cytotoxicity, high cellular uptake and
intracellular localization of these carboranylporphyrins in tumor cells are accomplished.
The synthesis of the tetra(4-nido-carboranylphenyl)porphyrin is also accomplished and
the comparative biological evaluation of the tetra(4-nido-carboranylphenyl)porphyrin and
the tetra(carboranylphenyl)tetrabenzoporphyrin in the tumor cells show lower toxicity
and better uptakes of these porphyrins in the cells. These porphyrins also show low
toxicity in the mice.
The syntheses of various novel neutral water soluble carboranylporphyrins is
accomplished. These novel carboranylporphyrins synthesized are water-soluble by the
functionalization of the carboranes with water-solubilizing groups such a polyethylene
glycol, hydroxyl and amine groups.
The synthesis of novel carboranylsapphyrins is attempted. Sapphyrins are penta pyrrolic
macrocycles and various methods for the synthesis of these macro cycles are attempted
and reported.
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Chapter 1
Introduction
1.1 Structure of Porphyrins
A porphyrin is an aromatic heterocyclic macrocycle made from one pyrrole subunit and
three pyrroline subunits, and linked on opposite sides through four methine bridges
(Figure 1-1).1 The extensive π-conjugation makes the compound chromatic, hence the
name "porphyrin" from a Greek word for purple.2 Porphyrins and related compounds are
the basic chromophores for a large number of biologically important natural products
such as heme, chlorophylls and bacteriochlorophylls.3 They also exist as contracted
structures such as corroles4 and expanded structures such as sapphyrins.5 Porphyrins are
being studied widely because of their intriguing physical, chemical and biological
properties.6

NH
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N

Figure 1-1: Structure of the porphyrin macrocycle

There are IUPAC and Fischer systems of nomenclature for porphyrins (Figure 1-2). The
IUPAC system assigns every carbon atom in the porphyrin with a unique number from 120 and the internal nitrogen atoms are numbered from 21-24.7 The Fischer system
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numbers the carbons at the pyrrolic β-positions as 1-8 and the four inter-pyrrolic carbons
(or the meso-carbons) as α, β, γ, and δ.8

3

7

5

8

NH
21

1

N
22

NH

23
HN

24

16
17

15

β

11

18

HN

N
8

12

14

N

δ

10
N

4

1

9

20
19

3

6

4

2

α

2

13

5
7

IUPAC

γ

6

Fischer

Figure 1-2: IUPAC and Fischer nomenclature

Porphyrins are aromatic macrocycles containing 22 conjugated π- electrons with 18 πelectrons participating in the delocalization pathway at a time while the other double
bonds are in cross conjugation. This conforms with the [4n+2] rule for aromaticity.
Porphyrins are highly colored and they show a characteristic intense Soret9 band at
around 400 nm with very high extinction coefficients. Porphyrins also have four satellite
bands between 450-700 nm known as Q bands.10 The Soret band is a major characteristic
of the optical spectra of the porphyrin macrocycle as it disappears with the disruption of
the macrocycle.11 The intensity and wavelength of the absorption bands changes with
variations in the peripheral positions of the porphyrin macrocycle. Protonation of two of
the inner nitrogen atoms or insertion of a metal into the porphyrin cavity also changes the
visible absorption spectrum. The 1H-NMR spectrum of the aromatic tetrapyrrole shows
2

anisotropic effects. 12-15 The highly shielded NH protons in the porphyrins appear at very
high field (-2 to -4 ppm) whereas the outer meso protons which are shielded by the
aromatic ring current appear at very low field (8 to 10 ppm).16, 17 The thermodynamically
most favored tautomers for symmetrically substituted porphyrins are the trans NH
tautomers. 18, 19, 20 The mechanism for N-H migration between trans- tautomers might be
proceeding in a stepwise manner through the less favored cis-tautomers (Figure 1-3).21
The most favored porphyrin structure is when the two inner hydrogens are bonded to
opposite nitrogens.22 When the inner hydrogens are bonded to adjacent nitrogens there
are Van der Waals interactions and so they are less stable.

NH

N

N

HN

NH

HN

N

N

N

NH

HN

N

Figure 1-3: Delocalization pathway in porphyrins

The porphyrin macrocycle is stable to concentrated sulfuric acid and trifluoroacetic acid
and unstable to perchloric acid, chromic acid and hydriodic acid. In the free-base
porphyrins the central nitrogen atoms are free and the NHs can be deprotonated with
strong bases such as alkoxides (pKa ~16) to form a dianion,23 while the two-imine
nitrogens can be protonated with acids such as trifluoroacetic acid. The NH protons react
with electrophilic reagents and can also be metalated. In the metalated porphyrins the

3

metal is chelated to the inner nitrogens with covalent and dative bonds and it helps in the
transmission of the electronic information from the metal ion and its axial ligands to the
porphyrin π-system. Two of the peripheral double bonds can undergo addition reactions
without interfering with the aromaticity. The β-pyrrolic positions are more sterically
favored than the meso-carbons and tend to undergo electrophilic substitution reactions
such as nitration, halogenation, sulfonation, formylation, acylation and deuteration.24, 25
1.2 Porphyrin Synthesis
The porphyrin synthetic chemistry depends on the fundamentals of symmetry and
complexity of the various substituents on the target porphyrin.26-29 The basic
methodologies for porphyrin synthesis and their chemistry were first developed by Hans
Fischer.30,

31, 32

Several methods for the synthesis of porphyrins using various

intermediates have since been developed.26 Most of the synthetic methodologies that will
be discussed in detail henceforth are important because some will be utilized throughout
this dissertation. There are many approaches to synthesize a porphyrin but only three
main methods will be discussed in this introduction. Firstly a simple tetramerization of
monopyrroles in the presence of an acid catalyst will be discussed, followed by the
MacDonald route using two dipyrromethanes, and finally the synthesis through
cyclization of an open chain tetrapyrrole will be discussed.
Porphyrin synthesis from monopyrroles33, 34, 35 is a simple and economical method. The
two famous model porphyrins that can be synthesized very easily using this procedure are
the octaethylporphyrin (OEP) 1.7 and the tetraphenylporphyrin (TPP) 1.4. The synthesis
of TPP 1.4 reported by Rothemund36,

37

involved a high temperature reaction between

pyrrole and benzaldehyde in pyridine, in a sealed tube. The conditions of this reaction
were modified by Alder, Longo and their colleagues.38, 39, 40 They used hot propionic acid
4

as a solvent (at atmospheric pressure) for the condensation of pyrrole 1.1 and
benzaldehyde 1.2 to get good yields of TPP 1.4 (20-25%). This reaction was further
optimized by Lindsey’s group using a two step reaction where the acid catalyzed
macrocyclization to form porphyrinogen 1.3 was followed by oxidation with 2,3dichloro-5,6-dicyanobenzo-1,4-quinone (DDQ) to form the tetraphenylporphyrin 1.4 in
excellent yields (Scheme 1-1).41
Ph
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Scheme 1-1: Tetraphenylporphyrin synthesis from monopyrrole using Lindsey’s
method41
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A wide variety of meso-tetraarylporphyrins were synthesized successfully using
Lindsey’s method. Lindsey’s method for the synthesis of tetraarylporphyrins was
followed throughout this dissertation since all the carboranylporphyrins synthesized in
this thesis are meso-substituted porphyrins.42, 43
The naturally occurring porphyrins do not contain meso-substituents and so the synthesis
of OEP 1.7 is the favored route for natural porphyrin synthesis. The two major routes for
the synthesis of OEP differ in the addition of the meso carbons. The substituents on the 3and 4- positions should be identical to get a unique product.44 In the first route for the
synthesis of OEP 1.7 the tetramerization of the substituted pyrrole 1.5 is done using
reagents such as formic acid which can provide the four meso methine carbons of the
product (Scheme 1-2).45

Et
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Et
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N
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HCHO
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(CH2=NMe2) IEt
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HN
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N

Et

Et
NMe2

1.7

Scheme 1-2: Octaethylporphyrin synthesis from substituted monopyrroles45
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In the second method pyrrole 1.6 bearing a 2-CH2R substituent is used for the
tetramerization; the methylene linkage will eventually be the source for inter pyrrolic
carbons.46-50 Large substituents on the monopyrroles are necessary to enforce a
polymerization of the elongating molecule into a cyclic porphyrin.
Dipyrromethanes are key intermediates in the synthesis of porphyrins by the [2+2]
MacDonald route. Symmetrical and unsymmetrical dipyrromethanes can be synthesized
using straightforward approaches such as self-condensation of bromomethylpyrroles51 or
by condensation of 2-acetoxymethylpyrroles52 with 2-unsubstituted pyrroles. MacDonald
and coworkers reacted 1, 9-di-unsubstituted dipyrromethane 1.8 with 1, 9diformyldipyrromethane 1.9 in the presence of hydroiodic acid catalyst to form pure
porphyrin 1.10 in high yields (Scheme 1-3).53
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Scheme 1-3: Porphyrin synthesis from dipyrromethanes by the [2+2] MacDonald route53
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The synthesis of unsymmetrically substituted porphyrins can be best achieved through
open chain tetrapyrrolic intermediates.54-58 The scrambling of pyrrole subunits during the
cyclization process can be avoided and the formation of only one porphyrin isomer can
be achieved. a,c-Biladienes are the most favored open chain precursors although a
number of open chain tetrapyrroles have been investigated and utilized in the synthesis of
the porphyrins.
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Scheme 1-4: Porphyrin synthesis from an open chain tetrapyrrole
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Symmetrical a, c-biladienes can be easily synthesized by reaction of a 1, 9-diacid
dipyrromethane 1.11 with formylpyrrole 1.12 as shown in Scheme 1-4.59 The a,cbiladiene is than cyclized using a Cu (II) salt to yield metalated porphyrin.

The

Cu(II)porphyrin is then demetalated to yield porphyrin 1.14 in high yields.60 Asymmetric
porphyrins can also be synthesized using the a,c-biladiene route via a tripyrrene.61 In the
cyclization of a,c-biladiene to porphyrin, the reaction is believed to proceed via a free
radical pathway where one of the methyl groups is lost while the other is retained as the
new methine carbon.62
1.3 Carboranes
A carborane is a cluster composed of boron and carbon atoms. Like many of the related
borans, these clusters are polyhedra, and are similarly classified as closo-, nido-,
arachno-, hypho-, etc. based on whether they represent a complete (closo-) polyhedron,
or a polyhedron that is missing one (nido-), two (arachno-), or more borons (Figure 14).63

H
H H

H

H
= BH
=C

Figure 1-4: closo and nido carborane cages
The most interesting feature of carboranes like 1, 2-C2B10H12 is the ability of the 2 carbon
atoms and 10 boron atoms to adopt the icosahedral geometry in which the carbon and the
boron atoms are hexa-coordinate.64,

65

Extremely stable icosahedral closo-ortho
9

carboranes have been explored for use in a wide range of applications from heat-resistant
polymers to medical applications.66 The o-carborane cage is very stable in the presence of
oxidizing agents, alcohols and strong acids and exhibits thermal stability to temperatures
up to 400 0C.67 At the temperature higher than 400 0C it rearranges first to metacarborane (1, 7- C2B10H12) and then to para-carborane (1, 12-C2B10H12) (Figure 1-5).68, 69,
70

H

H

H

H

H
H

= BH
=C

Figure 1-5: ortho (1, 2), meta (1, 7) and para (1, 12) carborane cages
1, 2-C2B10H12 is synthesized from decaborane. Decaborane is attacked by a Lewis base
complex of alkyl amines, alkyl sulfides, and acetonitrile, forming bis(ligand) derivatives
of B10H12L2, which in turn react with acetylene to give o-carborane in high yields
(Scheme 1-5).

71-74

This was the main route used for the synthesis of the o-carborane in

the following Chapters. Various substituted acetylenes have been reacted with B10H12L2
to form a variety of substituted carboranes. Acetylenes containing hydroxyl groups
destroy the decaborane cage and fail to give carborane products. So the carboranes
containing such groups are prepared by substitution reaction at the carbon. The strong
electron withdrawing o-carborane unit facilitates the metalation of the carborane C-H

10

group (Scheme 1-6).

75, 76, 77

This can then be followed by a substitution reaction with

alkyl or aryl halides.
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+

2L

B10H12L2
H

B10H12L2

+

H

+ H2

H
+ 2L + H2

H

= BH
=C

L = CH3CN, Alk3N, Alk2S

Scheme 1-5: Synthesis of ortho-carborane

H

H

H

+

Li

+

RLi
= BH
=C

Scheme 1-6: Reaction of ortho-carborane with n-BuLi
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RH

The substitution on the carbon of the o-carborane influences the reactivity of the
unsubstituted atoms. The generation of the anion with n-BuLi was widely used in the
following Chapters for obtaining different substituted carboranes.
The o-carborane moieties are extremely hydrophobic. The o-carborane cage can be
degraded by using pyridine/piperidine in 3:1 ratio.78 This mild method results in a nidocarborane cage where a boron is missing from the o-carborane to form the nido-C2B9H12-.
A loosely bound piperidine molecule is attached to the nido-carborane cage which can be
exchanged with either sodium or potassium ions to form a hydrophilic nido-carborane
cage. The attack of the base occurs on the most electropositive boron atom which is
directly attached to the carbon atoms. The removal of the boron generates a icosahedral
fragment with adjacent carbons on the open face. The extra hydrogen is assumed to be
bonded to the open face of the ion by a six-center hydrogen bond.79 The nido-carborane
cages can also be obtained by reaction of the closo-carborane cage with trialkylamines,80
methoxides,81 hydrazine82 and ammonia.83
The most interesting aspect of closo-carboranes and the nido-carborane compounds is
that upon irradiation with thermal (slow) neutrons, a nuclear fission reaction results,
breaking boron-10 atoms (which have 20% natural abundance) into an alpha particle, a
lithium atom, and some gamma radiation for application in boron neutron capture therapy
(BNCT). Carboranes, with their high boron content have been the molecules of choice for
boron delivery to tumors but are by themselves inadequate due to their hydrophobicity.
The carboranes are very stable in nature and so they can be incorporated into various
organic and biochemical substrates and can be used as vehicles for delivery of boron to
disease tissues which is critical to the success of BNCT. So a suitable balance between

12

the hydrophilicity of the nido-carborane cages and the hydrophobicity of the porphyrin
macrocycle will be essential to achieve specificity to tumors.
1.4 Boron Neutron Capture Therapy
BNCT84 has been experimentally tested primarily as an alternative treatment for
malignant brain tumors called glioblastomas. BNCT is a form of radio therapy that
utilizes a neutron beam that interacts with boron injected into a patient. BNCT depends
on the interaction of slow neutrons with boron-10 to produce highly cytotoxic particles
(4He+2 and 7Li+3) and the release of 2.4 meV of kinetic energy, according to Scheme 1-7.

4

10

5

B + 10n

11

5

2

He + 73Li + 2.79 MeV (6%)

B
4

2

He + 73Li + γ0.48 MeV + 2.31 MeV (94%)

Scheme 1-7: Nuclear reaction initiated by collision of a neutron with boron-10

Patients are first given an intravenous injection of a boron-10 tagged chemical that
preferentially binds to tumor cells. The neutrons are created either in a nuclear reactor or
by colliding high-energy protons into a Lithium target. The neutrons pass through a
moderator, which shapes the neutron energy spectrum suitable for BNCT treatment.
Before entering the patient the neutron beam is shaped by a beam collimator. While
passing through the tissue of the patient, the neutrons are slowed by collisions and
become low energy thermal neutrons. The thermal neutrons undergo reaction with the
boron-10 nuclei, forming an unstable boron-11 nucleus which then undergoes
spontaneous decay to lithium-7 and an alpha particle (Figure 1-6).
13

Figure 1-6: BNCT in cancer cells 85
14

Both the alpha particle and the lithium ion produce closely spaced ionizations in the
immediate vicinity of the reaction, with a range of approximately 5-9 µM, or one cell
diameter. This technique is advantageous since the radiation damage occurs over a short
range and thus normal tissues can be spared. Malignant brain tumors86 are usually highly
infiltrative of normal brain and the selective destruction of tumor cells and recurrence of
metastatic tumors can potentially be controlled or eliminated using such a therapeutic
modality. BNCT could dramatically increase patient life quality and expectancy.
BNCT relies on initial targeting of tumor cells by an appropriate compound attached with
10

B which preferentially concentrates in tumor cells. BNCT is a binary system of therapy

since the boron compound is made to target tumor cells and the neutron beam is aimed at
the location of the tumor. The advantage of such a therapy is that each component can be
manipulated independently of the other.
Thermal neutrons are not effective against deep seated tumors as they dissipate while
traversing the tissue and also thermal neutrons produce recoil protons capable of ionizing
tissue components.87 So the more energetic epithermal neutrons which become energized
when passing through the tissue are appropriate for BNCT.88 The source for the
epithermal neutrons is limited to nuclear reactors. The amount of neutrons that reach the
target area should not exceed the tolerance levels of the normal tissues. With BNCT we
can adjust the exact time when there is the highest differential amount of

10

B

concentrations in tumor than the normal tissues and then irradiation with a non
radioactive neutron beam for an optimum time will be highly toxic to the tumor cells.
Furthermore, the neutron beam itself can be directed in such a way that the normal tissues
with high 10B concentration can be excluded from the treatment zones.89, 90, 91
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Protection of normal tissues near and within the treatment areas is achieved by selective
targeting of 10B to the tumor. The alpha particles along with the high LET particles which
are produced after the splitting of boron-10 also have biological advantages. X-rays and
alpha particles do not require oxygen to enhance their biological effectiveness which is
not the case with other forms of ionizing radiation. A rapidly growing tumor tissue
frequently outgrows its own blood supply and so there are some regions within the tumor
tissue which receive far less oxygen than normal tissues. As a result of this oxygen
depletion, the tumor can become more resistant to the effects of conventional photon or
electron (i.e. low LET) radiation therapy. Even when the tumor has limited oxygen
supply the tumors will be sensitive towards the alpha particles. The alpha particles and
lithium ions can also kill dividing and non dividing tumor cells. This is greatly
advantageous since tumors are known to have a large number of viable but inactive cells.
Other forms of radiation therapy and also chemotherapy tend to work very well only on
cells that are dividing.92
The 10B which has a high cross section for capture of neutrons is also the favored nuclide
for the synthesis of BNCT agents with hydrolytically stable linkages between the boron
and other elements such as carbon, oxygen and nitrogen.

10

B nuclide93, 94, 95 produces

high LET particles and its small atomic size permits it to be replaced instead of carbon in
many of biologically active compounds. The use of

157

Gd as a nuclide96, 97 in GdNCT

(gadolinium neutron capture therapy) was also proposed since
section for the capture of neutrons than the

10

B.98

157

157

Gd has a larger cross

Gd on collision with neutron

produces γ rays and Auger and Coster-Kronig electrons.99 The γ rays are not confined to
the tumor cell from which they are produced and also the Auger and Coster-Kronig
electrons have low energy which makes them less effective away from the cell nucleus.
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The other nuclides that occur abundantly in tissue like 12C, 1H, 14N and 16O do not exhibit
a high nuclear cross-section for neutron capture.100 The high tissue concentrations of 1H
and 14N can contribute to secondary fission products. In order to minimize this secondary
effect it is essential that the 10B concentration is approximately 15-30 µg of 10B/gram of
tumor or 109 of
reaction.101,

102

10

B/cell so that 85% of the radiation dosage arises from

The cellular concentration of

10

10

B capture

B should be adequate and also highly

specific to tumors so that radiation dosage to the surrounding normal tissues can be
minimized.
The major challenge in BNCT has been the development of a 10B delivery agent that can
selectively destroy the glioblastoma multiforme (GSM) cells in the presence of normal
cells. An ideal BNCT agent which is tagged with 10B should be able to deliver therapeutic
and predictable concentrations of ~30 µg of

10

B per gram of tumor. The localization of

the 10B atoms within tumors in close proximity to the tumor cell nucleus compared to the
cell surface increases the therapeutic effect of the BNCT agent while decreasing the
required dosage amount. The ideal BNCT agent should have low toxicity towards the
normal tissue surrounding the tumor. It should also have low retention times in the tumor
and should be rapidly cleared from the blood and normal tissues. The

10

B agent should

have the propensity to cross the blood-brain barrier (BBB)103 which can be achieved with
good lipophilicity of the drug. The

10

B agent should be readily synthesized and should

have the ability to be easily monitored in the tissue for evaluation and quantification of
10

B-localization sites.

The quest for these ideal 10B agents started in 1950s and early 1960s when boric acid and
sodium borate were used with no success. These compounds were non selective and had
low tumor/brain ratios.104–107 In a search for a low toxic compound with a greater
17

persistence in tumor lead to the synthesis and biologically evaluation of 4dihydroxyborylphenylalanine (BPA) by Snyder et al.108,

109

Later disodium mercapto-

closo-dodecarborate (BSH) was synthesized and analyzed because of its higher
percentage of boron and a significantly lower toxicity based on its boron content.110 Both
BSH and BPA were chosen for clinical studies and are currently undergoing Phase I/ II
clinical trials in the US, Europe and Japan, for the treatment of patients with melanomas
and glioblastomas.111 However both BSH and BPA showed low selectivity for tumor
cells and low retention times in tumors.

SH
= BH
=B

Na2

(HO)2B

CO2
H

NH3

BPA

BSH

Figure 1-7: Structures of BSH (disodium-mercapto-closo-dodecarborate) and BPA (4dihydroxyborylphenylalanine)

Furthermore BSH is chemically unstable which increases its toxicity and BPA has only a
low percentage of boron by weight so a large dose is necessary for effective BNCT.112
For BNCT to be effective, there must be ~15-30 µg of
concentration (<5 µg of
blood.113,

114, 115

10

10

B/g of tumor and a low

B/g of normal tissue) in the surrounding normal cells and

Since BSH and BPA are not ideal BNCT agents several other BPA

derivatives and boron containing amino acids as well as non amino acids were

18

synthesized and evaluated.116-120 Highly water soluble carbohydrate derivatives of BSH
and other boron containing sugars were synthesized and evaluated both in vivo and in
vitro studies.121-127 These compounds showed low toxicity and uptake in tumor cells.
Various other boron-containing analogues of biologically active compounds such as
amino acids,128 peptides,129 nucleosides/nucleotides,130 phospholipids,131 liposomes,132
and monoclonal and bispecific antibodies have been synthesized and studied.133, 134
Of all the novel boron-delivery agents, carboranylporhyrins appear to be the most
promising tumor-selective compounds because of their ability to effectively accumulate
within neoplastic cells and to be retained there for long periods of time135 in addition to
exhibiting most of the desired characteristics of an effective BNCT agent.136 The primary
source of boron in the new BNCT agents is usually the hydrophobic o-carborane (oC2B10H11) or the amphiphilic nido-carborane (o-C2B9H11-). These carborane cages have
high boron content and display extraordinary thermal, kinetic and photochemical
stabilities relative to other boron clusters.137, 138 The carboranylporphyrins are porphyrin
macrocycles linked to carborane clusters via ester, amide, ether, methylene or aromatic
linkages. The nature of these linkages affects the stability of the compound and also its
toxicity. The carboranylporphyrins are fluorescent and so they can be easily detected and
quantified using fluorescence microscopy. The carboranylporphyrins usually have planar
aromatic structures and have demonstrated their ability to interact with the DNA.139 In the
following Chapters the synthesis and biological evaluation of highly stable
carboranylporphyrins with very high boron content will be further discussed. The novel
carboranylporphyrins synthesized are water soluble so that they can be administered
systemically and they are also amphiphilic compounds (suitable balance between the
hydrophilicity and lipophilicity) which make them highly promising compounds for
19

BNCT. The carboranylporphyrins discussed in later Chapters have the potential to
provide most favorable differential boron concentrations between the tumor and normal
brain. The synthesis of novel stable carboranylporphyrins and their in vivo and in vitro
toxicity and uptake studies will be discussed.
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Chapter 2
Synthesis and Invitro Biological Evaluation of a Tetra(nido-carboranyl)porphyrin
and an Octa(nido-carboranyl)porphyrin
2.1 Introduction
Boronated carboranylporphyrins are a novel variety of

10

B delivery agents currently

under investigation for Boron neutron capture therapy (BNCT).1-4 A tetra(nidocarboranyl)porphyrin and an octa(nido-carboranyl)porphyrin are the target mesosubstituted carboranylporphyrins of the present study described in this chapter. The major
challenge in the development of 10B-delivery agents has been the delivery of therapeutic
doses of boron to the target tumors with minimal normal tissue toxicity. The 10B delivery
agents have to be very selective towards the tumors, particularly towards high-grade
gliomas which are highly infiltrative of normal brain. The ability of carboranylporphyrins
to accumulate within tumors and their synthesis with high boron content has been
investigated.5 Water solubility is an important factor for a 10B-delivery agent so that it can
be administered easily into the blood stream. The lipophilicity is necessary for them to
cross the blood-brain barrier (BBB) and diffuse within the brain and the tumor.6
Therefore, amphiphilic compounds such as the target compounds tetra(nidocarboranyl)porphyrin and octa(nido-carboranyl)porphyrin will have a suitable balance
between hydrophilicity and lipophilicity. This will be of primary interest because they
should provide the most favorable differential boron concentrations between tumor and
normal brain, thereby enhancing tumor specificity. This critical feature of the
carboranylporphyrins along with easy synthesis and high boron content forms the basis of
their use as boron delivery vehicles for the BNCT of tumors.
Only two boron containing drugs are currently clinically approved for use in BNCT:
disodium mercapto–closo-dodecaborate (BSH)7 and L-4-dihydroxyborylphenylalanine
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(BPA).8 However both BSH and BPA have low selectivity for tumor cells and low
retention times in tumors.9 Furthermore BSH is chemically unstable and BPA has only
low percentage of boron by weight so a large dose is necessary for effective BNCT.
Among all the investigated

10

B delivery agents, carboranylporphyrins appear to be

particularly promising because of their demonstrated ability for targeting and selectively
accumulating in tumor cells.10, 11 The first series of the carboranylporphyrins synthesized
by Haushalter and Rudolph had the porphyrin macrocycle linked directly to carborane
moiety via carborane-carbon atom by a methylene or phenyl linkage for example 2.1.12, 13
These compounds were used as catalysts for reversible multi-electron reduction of small
molecules such as O2 and N2. Later several groups of researchers synthesized
carboranylporphyrins on the basis of natural porphyrins.14-17 Some of them showed high
solubility in water and accumulated in the tumor cells but their toxicity levels towards the
normal cells were too high.18 Kahl et al.19 reported a novel type of boronated porphyrin
2.2 in which four closo-carboranes were linked to the porphyrin macrocycle by ester
linkages. This carboranylporphyrin showed a better localization in the murine intracranial
glioma when compared to intact brain tissue. Morgan et al20 used hematoporphyrin as
starting compound in which carboranes were bonded to the carboxylic groups of
hematoporphyrin to give 2.3 making the porphyrin more hydrophilic. Miura et al21
synthesized carborane-containing metal porphyrins, for example 2.4, which showed
lower toxicity and a better accumulation in tumor as compared to blood. A number of
carboranyporhyrins have been synthesized by the Vicente et al.22 Some of the
carboranylporphyrins synthesized by Vicente et al have been shown to interact with DNA
and thereby produce in vitro DNA damage following light activation.23,
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Figure 2-1: Examples of carboranylporphyrins reported in literature

Porphyrin macrocyles containing up to 8 boron clusters (43 % boron by weight) attached
to the porphyrin macrocycle via ester, amide, ether, amine and carbon-carbon bonds have
been synthesized and evaluated in cellular and animal studies. Several of these have
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tumor-localizing abilities coupled with high boron content that enable them to cause
selective cell kill after irradiation with a very low intensity neutron beam. 25-29 Identifying
the mechanism of the localization of the carboranylporphyrins in tumors will allow the
subsequent design of new carboranylporphyrins with higher tumor to normal tissue ratio.
The carboranylporphyrins with the ester and amide linkages have questionable in vivo
hydrolytic stability. The tetra(nido-carboranyl)porphyrin30 synthesized in this study has
36 boron atoms/ molecule and 30% boron /by weight. It also has stable carbon-carbon
linkages between the porphyrin macrocycle and the carborane residues which will ensure
that in vivo cleavage, leading to release of free carborane, is highly improbable with these
compounds.31 Although the synthesis of one porphyrin derivative bearing eight boron
cages linked to the porphyrin ring via ester bonds has been reported,32 studies of its
biological properties were never undertaken. I synthesized a boron-containing porphyrin
with eight carborane cages (44% boron by weight) linked to the porphyrin macrocycle
via chemically stable carbon-carbon bonds and studied its biological properties. The
cellular and animal studies done on similar carboranylporphyrins by our group have
shown that these types of macrocycles are an excellent platform for the selective delivery
of boron to tumor cells.30 Both porphyrins H2TMCP and H2OCP show promise of
considerable higher therapeutic efficacy in BNCT because of their ability to deliver
therapeutic amounts of boron to tumors with low levels of toxicity. The tetra(nidocarboranyl)porphyrin and octa(nido-carboranyl)porphyrin are highly fluorescent and this
enables the detection of tumor cells using fluorescence microscopy,33,
determination of

10

34

and the

B-localization in tumors and surrounding tissues. Intracellular boron

distribution and quantification play an important role in determining the dose and length
of neutron radiation, as well as the success of the BNCT treatment.35 In this chapter the
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syntheses of a stable tetra(nido-carboranyl)porphyrin (H2TMCP) and an octa(nidocarboranyl)porphyrin (H2OCP) are described. Their dark toxicity, cellular uptake and
intracellular localization studies are reported and discussed.
2.2 Results and Discussion
2.2.1 Synthesis of a Tetra(nido-carboranyl)porphyrin
Tetra(nido-carboranyl)porphyrin 2.9 containing four carborane cages linked via carboncarbon bonds to the meso-phenyl on the porphyrin macrocycle was prepared according to
Scheme 2-1.22, 30 Porphyrin 2.9 was prepared in four steps from commercially-available
4-(bromomethyl)bromobenzene 2.5, as previously described.22, 30 Reaction of the lithium
anion36 of 1-methyl–o-carborane with 4-(bromomethyl)bromobenzene 2.5 by an SN2

-

substitution reaction produced 4-(1-methyl-o-carboranyl)methyl]bromobenzene 2.6 in
75% yield. 4-(1-Methyl-o-carboranyl)methyl]benzaldehyde 2.7 was prepared from 4-(1methyl-o-carboranyl)methyl]bromobenzene 2.6, by lithium-bromide exchange at -780C,
followed by addition of DMF and acidic hydrolysis to form the product in 60% yield.37
Condensation of 4-(1-methyl-o-carboranyl)methyl]benzaldehyde 2.7 with pyrrole under
Lindsey-type conditions38 (using 0.01 M of pyrrole and 0.005 M TFA ) afforded
tetra(closo-carboranyl)porphyrin 2.8 in 30 % yield. The resulting porphyrin 2.8 has high
hydrophobic character and so is soluble in non polar organic solvents like carbon
tetrachloride. The conversion of the closo-carborane cages into nido-carborane cages was
done by a mild procedure using 3:1 mixture of pyridine and piperidine,39 at room
temperature for 36 hours. The tetra-sodium salts were obtained by piperidinium/Na+
cation exchange on a Dowex 50WX2-100 resin in the sodium form. Pure tetra(nidocarboranyl)porphyrin 2.9 was obtained in 90% yield and was highly soluble in polar
solvents such as acetone, methanol, DMSO and water.
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The highly pure tetra(nido-carboranyl)porphyrin 2.9 was synthesized in good yields in
order

to

study

and

compare

the

biological

properties

with

octa(nido-

carboranyl)porphyrin. Porphyrin 2.9 has chemically stable carbon-carbon methylene
linkages between the meso-phenyl substituents and the carborane moieties. The H2TMCP
has 36 atoms of boron per molecule which makes it 30 % boron by weight of the
molecule and so has the potential to deliver therapeutic concentrations of boron to tumor
cells for the BNCT. The water soluble H2TMCP is tetra anionic and was found to have
the highest hydrophobic character compared to other carboranylporphyrins previously
studied. The negatively charged nido-carborane cages make the H2TMCP water-soluble
while the phenyl rings enhance the hydrophobicity.40 The amphiphilic character is very
desirable in promising BNCT agents since it helps with the solubility of the drug in the
blood and also with crossing of lipophilic membranes.41 The distribution of the carborane
cages at the porphyrin periphery might influence the cytotoxicity, cellular uptake and the
retention in the sub-cellular organelle. The UV-visible of the porphyrin 2.8 is similar to
that of typical meso-substituted porphyrins42 with a soret band at 419 nm and four Q
bands showing etio-type absorption spectrum. The H2TMCP 2.9 shows an intense Soret
band in acetone and less intense broader bands in water and human serum. The carborane
cages do not quench the fluorescence of porphyrin 2.9 as it shows fluorescence at 667 nm
upon excitation at 543 nm. The high fluorescence emission helps in the detection of the
H2TMCP 2.9 in tumor cells using fluorescence microscopy. The pure H2TMCP was
characterized by

1

H-NMR and MALDI-MS. The

1

H-NMR of the tetra(nido-

carboranyl)porphyrin shows the BH protons of the open face of the nido-carborane cages
as broad singlet between -2.45 to -1.9 ppm and the remaining BH protons at 0.9-2.4 ppm
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whereas in the closo-carborane cages of the porphyrin 2.8 the BH protons appear between
1.5-3.4 ppm. The porphyrin macrocycle 2.8 exhibits a non-planar waved conformation.43

Figure 2-2: Crystal structure of H2TMCP
In order to study the interaction of the porphyrins with human serum an experiment with
H2TMCP 2.9 in mixture of human serum and PBS solution at pH = 7.2 was performed.
Equal concentrations of the porphyrin was added to increasing concentrations of human
serum (from 0-2%) in PBS solution at pH = 7.2. The measured visible (Figure 2-3) shows
the characteristic sharp (red) peak of porphyrin in DMSO and the short broad peak
(black) of the porphyrin in 0% human serum which is a characteristic of an aggregated
36

porphyrin. As the human serum concentration increases the Soret band becomes sharper
and resembles that of the H2TMCP in DMSO which shows that the porphyrin is deaggregating and probably binding to proteins within human serum.

Figure 2-3: H2TMCP in DMSO (red) and 0-2% human serum (HS) in PBS (other
colors).

2.2.2 Synthesis of a Octa(nido-carboranyl)porphyrin
Porphyrin 2.17 was obtained in seven steps using the same synthetic methodology as
described for porphyrin 2.9 (Scheme 2-2).22 The carborane cages are linked by a
methylene linkage at the meta-positions of the meso-phenyl rings on the porphyrin
macrocycle. Di(bromomethyl)bromobenzene 2.11 was obtained from commercially
available 3,5-dimethylbromobenzene 2.10 via a free radical substitution reaction in the
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presence of NBS and benzoyl peroxide.44 The yield of this reaction was 33%.
Di(bromomethyl)bromobenzene 2.11 reacted with two equivalence of

1-lithium-2-

methyl-o-carborane in THF via an SN2 reaction to form bis[3,5-(1-methyl-ocarboranyl)methyl]bromobenzene 2.12 in 63% yield.

Br

Li

Br
NBS
bezoyl peroxide
CCl4

CH3

CH3

Br

Me

THF
Me
LiI
Br 63%

33%
Br

Me

2.11

2.10

1. n-BuLi
THF, -78oC
2. DMF
3. HCl
70%

2.12

CHO

Me

1. Pyrrole, TFA
2. p-Chloranil

Me

Me

Me

Me

10%

Me

2.13
NH
N

N
HN

Me

Me
Me

Me

= BH
=C

2.14

Scheme2-2: Synthesis of Octa(closo-carboranyl)porphyrin 2.14.
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A lithium-bromide exchange was then performed on the bromobenzene 2.12, followed by
reaction

with

DMF

and

acidic

hydrolysis,

to

afford

bis[3,5-(1-methyl-o-

carboranyl)methyl]benzaldehyde 2.13 in 70% yield. This aldehyde 2.13 was condensed
with pyrrole using Lindsey-type conditions (using 0.01 M of pyrrole and 0.005 M TFA )
followed by oxidation of the porphyrinogen intermediate with p-chloranil to give the
octa(closo-carboranyl)porphyrin 2.14 in 10% yield. Porphyrin 2.14 has high hydrophobic
character and it is soluble in non polar organic solvents, such as carbon tetrachloride and
toluene. Addition of one drop of acid such as TFA, increases solubility of 2.14 in
chloroform and dichloromethane, via formation of the porphyrin dication. The porphyrin
2.14 is found to protonate readily, possibly due to the inductive effect of the carborane
cages.23 The porphyrin 2.14 was characterized by 1H-NMR, MS, UV-Vis and X-ray
crystallography. Crystals of porphyrin 2.14 were grown from slow diffusion of
cyclohexane into a concentrated solution of 2.14 in dichloromethane. Figure 2-4 shows
the crystal structure of the free base porphyrin 2.14. The porphyrin macrocycle 2.14
exhibits a planar conformation with the meso-phenyl rings orthogonal to each other and
to the porphyrin plane. The closo H2OCP 14 was made into a nido H2OCP 17 by the deboronation of the eight carborane cages using pyridine/piperidine mixture in 3:1 ratio for
72 hours.45 This resulted in very low yields of porphyrin 2.17 so an alternate route was
employed. In this new route the water-insoluble porphyrin 2.14 was first metalated46 with
Zn2+ to protect the inner NHs. The UV-visible data clearly showed the disappearance of
the absorption bands at 513nm, 591nm and 651nm indicating the Zn insertion. The
metallation was followed by the deboronation of the carborane cage using
pyridine/piperdine mixture in 3:1 ratio. This was then made into a sodium salt by the
piperdinium/Na+ exchange on a Dowex 50WX2-100 resin, to form water-soluble
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Figure 2-4: The molecular structure of porphyrin 2.14 as determined by X-ray
crystallography. (a) top view; (b) side view. Solvent molecules and H atoms,
except for N-H, are not shown
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porphyrin 2.16. Porphyrin 2.16 was de-metallated using TFA to give the octa(nidocarboranyl)porphyrin 2.17 in 90% yield.47 H2OCP 2.17 was further purified by passing it
through a sephadex column to remove low molecular weight impurities. The base
induced deboronation reaction gave a good yield of the corresponding octa(nidocarboranyl)porphyrin when performed on the zinc(II)complex 2.16, rather than on the
free base 2.14. The demetalation also occurred smoothly under acidic conditions.
Most of the carboranylporphyrins synthesized before had 2 or 4 carborane cages attached
to the porphyrin macrocycle by weak linkages which affected their stability in the in vivo
environment. The charge, amphilicity and the structural features also affect the uptake in
the tumor cells and their toxicity. The H2OCP has eight carborane cages attached by
hydrolytically stable methylene linkages to the phenyl positions on the porphyrin
macrocycle. The H2OCP 2.17 has a total of 72 borons which makes it an effective BNCT
agent since it can potentially deliver 15-30 µg of Boron-10/gram of tumor. The H2OCP
2.17 is octa-anionic and shows good solubility in polar solvents whereas the closo
carborane analog 2.14 is soluble in non polar solvents. The perfect balance of the
hydrophobicity and the hydrophilicity48 found in both the H2TMCP and the H2OCP helps
in the easy uptake of these carboranylporphyrins by tumor cells. Porphyrin 2.17 had to be
very pure for in vitro and in vivo studies as free nido carborane impurity in the compound
is known to be toxic to cells or animals and this can totally alter the toxicity studies. The
UV-visible showed a characteristic porphyrin Soret band at 420 nm and the four Q bands
in etio-type absorption spectra (Figure 2-5).42 The H2OCP is fluorescent and it has the
excitation wavelength at 557 nm and the emission wavelength at 607 nm. The
fluorescence emission helps in the detection of the intracellular localization of H2OCP in
tumor cells using fluorescence microscopy.
42

Figure 2-5: UV-visible of the H2TMCP (in blue) and H2OCP (in green) in Acetone

The 1H-NMR of the octa(nido-carboranyl)porphyrin 2.17 shows a broad singlet at -2.4
ppm indicating the BH protons on the open faces of the eight carborane cages. The
remaining 72 protons are between 1.6-2.9 ppm. The 24 methyl protons on the carborane
cages form a singlet at 2.0 ppm. The aromatic protons on the benzene ring are between
7.86-8.06 ppm and the β-H on the pyrrole are at 9.91 ppm.
2.2.3 Dark Cytotoxicity
The biological properties of nido-carboranylporphyrins H2TMCP 2.9 and H2OCP 2.17
were investigated and compared. Cell toxicity studies were conducted to evaluate the
toxicity levels of these porphyrins towards V79 hamster fibroblast cells using a
clonogenic assay.49, 50 The cells were exposed to different concentrations of porphyrins
(0-250 µM) and incubated for 24 hours and then their toxicity levels were determined by
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counting the survival cell colonies as shown in Figure 2-6. Concentrations of H2OCP up
to 200 µM did not show any significant effect on cell colony proliferation, but after 200
µM there was a decrease in the cell proliferation. H2TMCP showed more toxicity towards
the V79 fibroblast cells than H2OCP. H2TMCP concentrations up to 150 µM had no
significant effect on the rate of the cell colony proliferations but there was a decrease in
the number of colonies at the higher concentrations. The CS50 value which shows the
50% inhibition of the cell colony proliferation compared to the controls is above 250 µM
for both porphyrins. The determined survival rates above 100% are within the experiment
error range, which mainly derives from the heterogeneous nature of cell suspensions and
cell counting.

Figure 2-6: Cytotoxicity of (in green) H2OCP 2.17 and (in blue) H2TMCP 2.9 towards
V79 cells using a clonogenic assay.
44

V79 hamster fibroblast cell mimic the normal cells surrounding the tumor cells so less
toxicity against these cells will be advantageous in the development of an ideal 10B agent.
The death of normal cells around the tumor is an important drawback of chemotherapy,
however it can be avoided in BNCT by using a non toxic

10

B agent which can localize

preferentially in the tumor cells. Carboranylporphyrins H2TMCP and H2OCP have CS50 ≥
250 µM showing very low dark toxicity towards V79 hamster fibroblast cells using a
clonogenic assay. The dark toxicity of H2TMCP is in agreement with the tetra
carboranylporphyrins previously studied. 24, 51 But the low level of toxicity of octa(nidocarboranyl)porphyrin compared to tetra(nido-carboranyl)porphyrin is very promising as it
has more boron content and still shows similar low dark toxicity found in tetra
carboranylporphyrins.
2.2.4 Cellular Uptake
The concentration-dependent uptake was investigated in human T98G cells exposed to
concentrations up to 200 µM of H2OCP for 3 hours. The results obtained are shown in
Figure 2-7. The concentration of the intracellular bound porphyrin was determined by the
chemical extraction of the cells followed by the fluorescence detection using the
excitation filter of 570-580 nm and emission filter of 650 nm. The H2OCP accumulation
consistently increased with the increasing exogenous drug concentration. The uptake of
the porphyrin H2OCP into T98G human glioblastoma cells was found to be concentration
dependent. For H2OCP the amount of porphyrin accumulated in the tumor cells increased
continuously until the exogenous porphyrin concentration increased to 50 µM. For higher
concentrations of 50 µM - 200 µM the porphyrin accumulated in the cells did not show a
linear increase with the exogenous concentration.
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Figure 2-7: Concentration-dependent uptake of H2OCP 2.17 by T98G cells, after a 3
hour time period
This deviation might be because of the saturation of the H2OCP in the cells leading to
egression of excess porphyrin into the surrounding medium. The H2OCP with its -8
charge showed high aggregation in PBS solution and so H2OCP might be taken up by
phagocytosis. Residual toxicity affects of the H2OCP also might have affected the
concentration dependent uptake.
The concentration dependent uptake of H2TMCP in human HEp2 cells was also
investigated by exposing the cells to concentrations from 0-200 µM for 3 hours. The
fluorescence filters used for H2TMCP were the excitation filter of 540 nm and the
emission filter of 660 nm. The H2TMCP also showed a systematic increase in the
accumulation of the porphyrin in the T98G cells with an increase of exogenous drug
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concentration. The H2TMCP was tested for uptake in human HEp2 cells under the same
conditions used for the uptake of H2OCP in T98G cells.

Figure 2-8: Concentration-dependent uptake of H2TMCP 2.9 by Hep2 cells, after a 3
hour time period.
The H2TMCP showed a similar concentration dependent accumulation in HEp2 cells.
The Figure 2-8 shows a consistent increase in the uptake of the H2TMCP with external
concentration of the porphyrin.
The time dependent uptake of H2OCP, ZnOCP and the H2TMCP were investigated in
human T98G cells at the concentration of 10 µM. All the porphyrins were evaluated
under the same conditions for a period of 24 hours and the results are shown in Figure 29. At each time point the concentration of H2TMCP in the T98G cells was more than
either that of H2OCP and ZnOCP 2.16.
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Figure 2-9: Time-dependent uptake of H2OCP 2.17 (green), ZnOCP 2.16 (black) and
H2TMCP 2.9 (blue) at 10 µM by T98G cells
In the first four hours the amounts of all the three porphyrins accumulated in the cells
increased briskly. Both the H2TMCP and H2OCP concentrations in the T98G cells
reached a plateau after four hours whereas the ZnOCP 2.16 showed a consistent increase
in concentration over the 24 hour uptake time period. The H2TMCP is taken up to a
significantly higher extent by the T98G cells compared with the octa(nidocarboranyl)porphyrins

2.16

and

2.17.

The

accumulation

of

the

octa(nido-

carboranyl)porphyrins 2.16 and 2.17 was found to be time dependent.52 The tetra(nidocarboranyl)porphyrin is also found to be time dependent and accumulated to a much
higher extent than porphyrins 2.16 and 2.17. This might be due to the higher hydrophobic
character of the H2TMCP compared with the H2OCP and the ZnOCP 2.16. The uptake
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kinetics of the H2TMCP and the H2OCP appear to be similar as they both are taken up
rapidly in the first four hours and then reach a plateau. There is also difference in the
accumulation rates of the H2OCP and ZnOCP. The ZnOCP was taken up at a slower rate
than the metal free porphyrins H2OCP and H2TMCP but at the end of the 24 hour uptake
period the amounts of the Zn(II)complex 2.16 and the H2OCP found in the T98G cells
was very similar. The octa(nido-carboranyl)porphyrins 2.16 and 2.17 might have
different biological mechanism of uptake into the tumor cells and this may be the result
of their aggregation behavior and also isomer composition.53 The aggregated porphyrins
are presumed to be taken up easily than the non-aggregated porphyrins.23 Though the
octa-carboranylporphyrins 2.16 and 2.17 are taken up only half of that of the H2TMCP,
the octa-carboranylporphyrins 2.16 and 2.17 have higher boron content and can
potentially deliver therapeutic amounts of boron to tumors with low toxicity to the
normal cells. The more hydrophilic octa-anionic porphyrins could induce more damage to
the tumor tissue than the tetra-anionic porphyrins.
2.2.5 Intracellular Localization
The preferential sites of the localization of H2OCP 2.17 in T98G cells were investigated
using a Zeiss axiovert fluorescence microscope. Initially the T98G cells were observed
using the 63X/1.4 na plan-apochromatic oil immersion lens in the phase-contrast mode
and then the cells were exposed to UV-visible light using a texas-red filter, DAPI filter
and FITC filter to check for auto- fluorescence. The cells were exposed to 50 µM
concentration of porphyrin 2.17 for 4 hours and then observed under fluorescence
microscope using the texas red filter. They were also checked for fluorescence using the
DAPI and FITC filters since the organelle trackers emit fluorescence signal in these filter
sets.
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Figure 2-10: Intracellular localization of H2OCP 2.17 in human T98G cells. A: Phase
contrast; B: Porphyrin fluorescence; C: LysoSensor Green fluorescence; D: Overlay.
Scale bar: 20 µm
As seen in the Figure 2-10B the intracellular localization of the H2OCP 2.17 under the
texas red filter showed a pattern similar to that of localization in the lysosomes.
Lysosomes are small granule like organelles that are spread throughout the cytoplasm of
the cells. When cell cultures with H2OCP 2.17 were incubated with lysosome-specific
dye LysoSensor, a co-localization experiment was performed, as shown in Figure 2-10 C
and D. The signals from the Lysosensor were imaged using the FITC filter set (Figure 210 C). The overlay of Figure 2-10 B and C, as shown in Figure 2-10 D, shows that both
the porphyrin fluorescence and that of LysoSensor are localized in the same organelle.
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The H2OCP was found to localize preferentially in the cell lysosomes of the T98G
cells.54, 55 Negatively charged porphyrins are often known to localize subcellularly in the
lysosomes because of the low internal pH of the lysosomes.56 One of the proposed
mechanisms of porphyrin uptake into the tumor cells in humans involves their transport
by the plasma lipoprotein, human low-density lipoprotein (LDL), for which the
amphiphilic carboranylporphyrins have a high affinity. Since it has been known that the
tumor cells have increased number of LDL receptors, the process of receptor-mediated
endocytosis was suggested. This is thought to be followed by the maturation of the
endolysosome into a lysosome.57 The presence of the carboranylporphyrins in the acidic
environment of the lysosomes has been reported before. The proposed lowering of the
tumor pH in vivo due to the conversion of the glucose to lactic acid through the glycolytic
pathway under anaerobic conditions may also facilitate the process of porphyrin
localization.58
Using the same techniques and instrumentation as used for the microscopy of the H2OCP
the intracellular localization of the H2TMCP was also performed. The H2TMCP showed
similar localization to that of the H2OCP in the lysosomes. When Lysosensor was added
to the T98G cells with H2TMCP, under the FITC filter the Lysosensor in the lysosomes
was observed (Figure 2-11). When excited under the texas red filter the fluorescence
emitted by the H2TMCP was observed (Figure 2-11 B). The overlapped image (Figure 211 D) shows the coloration formed by the overlap of the green from the Lysosensor and
the red from the H2TMCP, indicating that H2TMCP is localizing in the lysosomes of the
T98G cells. These results are in accordance with the studies on anionic compounds which
preferentially target cell lysosomes, which are characterized by low internal pH.
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Figure 2-11: Intracellular localization of H2TMCP 2.9 in human T98G cells. A: Phase
contrast; B: Porphyrin fluorescence; C: LysoSensor Green fluorescence; D: Overlay.
Scale bar: 20 µm
The prefential sites of sub-cellular localization of tetra(nido-carboranyl)porphyrin 2.9 are
in the cell lysosomes. If the same situation occurs in the humans, an effective tumor cell
destruction can be achieved by release of the high LET particles intracellularly in the
lysosomes.
2.3 Conclusions
The total syntheses of highly promising BNCT agents tetra(nido-carboranyl)porphyrin
2.9 and octa(nido-carboranyl)porphyrin 2.17 in reasonable yields were accomplished.
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The nido carborane cages of H2TMCP and H2OCP make them water-soluble and
amphiphilic. The amphiphilic character is directly responsible for the ready uptake of
these porphyrins, H2TMCP and H2OCP, into cells in vitro. But both the porphyrins
H2TMCP and H2OCP display low dark toxicity towards V79 hamster fibroblast cells
(CS50 > 250 µM) using a clonogenic assay. The water-soluble tetra(nidocarboranyl)porphyrin shows more dark toxicity than the octa(nido-carboranyl)porphyrin.
Lower toxicity of the H2TMCP and H2OCP is an important parameter since it allows the
administration of a higher drug dose for a therapeutic effect. The cellular uptake of
H2TMCP and H2OCP is both concentration- and time-dependent. The tetra-anionic
porphyrin 2.9 accumulated to a higher extent in human glioblastoma T98G cells when
compared to the octa-anionic porphyrins 2.16 and 2.17, probably as a result of their
higher hydrophilicity. In the time-dependent cellular uptake studies, the Zn(II)OCP
complex 2.16 accumulated at a slower rate over 24 h than the metal free porphyrins
H2TMCP and H2OCP . H2TMCP showed higher uptake into T98G cells over 24 h than
the H2OCP. Both H2TMCP and H2OCP showed similar pathway of rapid accumulation in
the cells in the first four hours and then reached a plateau. The metal free H2OCP 2.17
accumulated at a faster rate and to higher extent in T98G cells than its Zn(II) derivative
2.16 at short time periods (up to 8 h), although similar amounts of 2.16 and 2.17 were
found after 24 hours, demonstrating different uptake kinetics for these two porphyrins.
The high cellular uptake of H2TMCP and H2OCP at lower concentrations is necessary to
deliver therapeutic amounts of boron to the tumor cells at low toxic levels. The
preferential sites of subcellular localization of H2TMCP and H2OCP in human
glioblastoma T98G cells are the cell lysosomes, possibly as a result of their anionic
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nature and/or endocytic uptake. A similar situation in vivo will result in tumor cell
destruction with the intracellular release of the LET particles.
2.4. Experimentals
Chemistry: All experiments were performed under argon atmosphere in oven dried
glassware. Commercially available starting materials were purchased from Sigma-Aldrich
and used without further purification. Methyl carborane was purchased from Dexsil.
Solvents used as reaction media were distilled immediately before use; THF and toluene
were distilled from Na/ benzophenone. Methylene chloride was distilled from calcium
hydride. 1H-NMR spectra were recorded on a Brucker AC-250 (250 MHz 1H) spectrometer
in deuterated chloroform (CDCl3: 7.26 ppm) and deuterated acetone (CD3OCD3 : 2.05 ppm).
Chemical shifts (δ) are given in parts per million relative to tetramethylsilane (TMS, 0 ppm);
multiplicities are indicated as br (broad), s (singlet), d (doublet), t (triplet), q (quartet) and m
(multiplet).
Analytical TLC was performed on Scientific Adsorbent Company Inc. silica gel plate.
Flash column chromatography was performed using silica gel (Scientific Adsorbent
Company Inc. 40-63 µm particle size, 60 A0 pore size). Electronic absorption spectra
were measured using a Perkin-Elmer Lambda 35 UV-vis spectrophotometer. Mass
spectra were obtained at LSU Mass Spectrometry Facility.
[4-(1-methyl-o-carboranyl)methyl]bromobenzene (2.6): A two necked round bottom
flask containing 1-methyl-o-carborane (5.00 g ,31.65 mmol) in dry DME(150 ml) was
cooled down to 0oC under argon. n-BuLi (20 ml, 1.6 M in hexane) was added dropwise
and the resulting mixture was stirred as 0oC for 30 min. A solution of 4(bromomethyl)bromobenzene ( 7.91 g, 31.65 mmol) in dry DME(15 ml) was added drop
wise. After stirring at 0oC for 10 min the final reaction mixture was warmed to room
54

temperature and subsequently refluxed for 10 h under argon. The solvent was then
removed under vacuum and the crude solid obtained was purified by recrystallization
from dichloromethane/methanol to give the title compound (7.80 g, 75% yield) as white
crystals, mp127-128 oC. MS (EI) m/e 327.1 (M+), 1H-NMR (CDCl3) δ 1.3-3.0 (br, 10 H,
BH), 2.15 (s, 3H, CH3), 3.41 (s, 2H, CH2), 7.06 (d, 2H, Ar-H), 7.48 (d, 2H, Ar-H).
[4-(1-methyl-o-carboranyl)methyl]benzaldehyde (2.7): A solution of compound 2.6
(4.00 g ,12.23 mmol) in THF ( 150 ml) under argon was cooled to –78o C. n-BuLi (7.6
ml, 1.6 M in hexane )was added drop wise while maintaining the temperature at -78 oC.
The reaction mixture was stirred at -78 oC for 30 min before dry DMF (5.0 ml, 64.6
mmol) was slowly added. The final reaction mixture was stirred at -78oC for 15 min and
then warmed slowly to room temperature. A 2N HCl solution (150 ml) was added and the
reaction mixture was for 2h at room temperature. The solution was then reduced to 200
ml and extracted into CH2Cl2 (4*50 ml). The organic extracts were washed once with
aqueous saturated NaHCO3, once with water and dried over anhydrous Na2SO4. After
removal of the solvent under vacuum, the oily residue was purified by column
chromatography on silica gel (CH2Cl2/petroleum ether,1:1), yielding the title compound
(2.00 g, 62% yield ) as a white solid , mp 96-98 o C, MS (EI) m/e 276.1 (M+) . 1H-NMR
(CDCl3) δ 1.5-3.0 (br, 10 H, BH), 2.19 (s, 3H, CH3), 3.54 (s, 2H, CH2), 7.38 (d, 2H, ArH), 7.89 (d, 2H, Ar-H), 10.04 (s, 1H, CHO).
Meso-tetra[4-(1-methyl-o-carboranyl)methylphenyl]porphyrin(2.8): A solution of the
aldehyde 2.7 (1.16 g, 4.19 mmol) and freshly distilled pyrrole (0.30 ml, 4.32 mmol) in
dry CH2Cl2 (420 ml) was purged with argon for 15 min. TFA (0.25 ml, 3.15 mmol) was
added to the solution and the mixture was stirred at the room temperature under argon for
20 h (complete disappearance of starting compound monitored by TLC ). After addition
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of p-chloranil (0.788 g, 3.14 mmol) the reaction mixture was stirred at room temperature
for 2 h. The solution was concentrated under vacuum to 200 ml, and then washed once
with aqueous saturated NaHCO3, and once with water before being dried over anhydrous
Na2SO4. The residue obtained after removal of the solvent under vacuum was purified by
the column chromatography on the silica gel (CH2Cl2/petroleum ether 1:1) and the fastest
running porphyrin fraction was collected and recrystallized from CH2Cl2/methanol,
yielding 0.375 g (32.1% yield )of the title compound as purple crystals , mp >300 0C .
MS (MALDI) m/e 1296.0 (M+). 1H-NMR (CDCl3) δ -2.80 (br, 2H, NH), 1.6-3.1(br, 40
H, BH), 2.34 (s, 12H, CH3), 3.81 (s, 8H, CH2), 7.59 (d, 8H, Ar-H), 8.20 (d, 8H, Ar-H),
8.85 (s, 8H, β-H). UV-Vis (CHCl3) λmax 419 nm (ε 444,700), 514 (15,400), 548 (7200),
588 (5100), 644 (3800).
Meso-tetra[4-(1-methyl-nido-carboranyl)methylphenyl]porphyrin tetrasodium salt
(2.9): Porphyrin 2.8 (0.050 g,0.0386 mmol) was dissolved in a 3:1 mixture of pyridine
and piperdine (4.0 ml), and stirred at room temperature in the dark for 36 h, under argon.
The solvent was completely removed under vacuum, the residue redissolved in 40%
aqueous acetone and passed slowly through a Dowex 50WX2-100 resin in the sodium
form. The porphyrin fraction was collected, dried under vacuum, redissolved in 70%
aqueous acetone and again passed through the ion-exchange resin. After removal of the
solvent under vacuum, the tetraanionic porphyrin was got as pure crystalline solid.
Mp>300 oC MS m/e 1408.60, 1H-NMR (CD3OCD3) δ : -2.70(s , 2H, NH) ,-2.45 to –1.90
(br, 4H, BH), 0.9–2.40 (br, 32H, BH) 1.59 (s, 12H, CH3), 3.50 (s, 8H, CH2), 7.81 (d, 4H,
Ar-H), 8.08 (d, 8H, Ar-H), 8.90 (s, 8H, β-H). UV-Vis (CH3OCH3) λmax: 419 nm (ε
349,700), 514 (13,600), 548 (12,400), 594 (4100), 650(6000).
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Bis-(3,5-bromomethyl)bromobenzene (2.11): To a refluxing solution of 3,5dimethylbromobenzene 2.10 (4.63 g, 25.0 mmol) in dry CCl4 (300 ml) under Argon,
were added NBS (9.79 g, 55.0 mmol) and benzoyl peroxide (0.80 g, 3.30 mmol) in
portions, over a one hour period. The final reaction mixture was refluxed with stirring
and under Argon for 16 hours. After cooling to room temperature, the reaction mixture
was filtered and the filtrate washed once with an aqueous saturated solution of NaHCO3
and once with water. The organic solution was dried over anhydrous Na2SO4 and the
solvent evaporated under vacuum. The resulting residue was purified by column
chromatography using dichloromethane/petroleum ether 1:9 for elution, and the main
product collected and recrystallized from n-hexane, yielding 2.83 g (33% yield) of the
title and literature known compound, m.p. 98-101o C. MS m/e 342.8. 1H-NMR (CDCl3) δ
: 4.40 (s, 2H, CH2), 7.34 (s, 1H, Ar-H), 7.47 (s, 2H, Ar-H).
Bis[3,5-(1-methyl-o-carboranyl)methyl]bromobenzene (2.12): n-BuLi (5.2 ml, 1.6 M
in hexane) was added dropwise to a solution of methyl-o-carborane (1.39 g, 8.80 mmol)
in dry THF (80 ml), at a temperature between -5o and 0o C, under Argon. The mixture
was stirred at this temperature range for one and a half hours, then cooled to -15o - -20o C
(ice/salt bath). A solution of LiI (0.166 g, 1.27 mmol) in dry THF (15 ml) and compound
2.11 (1.372 g, 4.00 mmol) in THF (20 ml) was added and the final reaction mixture
allowed to warm up to room temperature and stirred for 16 hours. After quenching the
reaction with water the resulting mixture was extracted four times with diethyl ether. The
organic extracts were washed once with water, once with brine, dried over anhydrous
Na2SO4 and the solvent removed under vacuum. The crude product was purified by
column chromatography using dichloromethane/petroleum ether 2:8 for elution, and the
main product collected and recrystallized from n-hexane to give 1.26 g (63% yield) of the
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title compound, m.p. 239-241o C. MS m/e 497.3; 1H-NMR (CDCl3) δ : 1.4-3.0 (br, 20H,
BH), 2.17 (s, 6H, CH3), 3.43 (s, 4H, CH2), 6.96 (s, 1H, Ar-H), 7.31 (s, 2H, Ar-H).
Bis[3,5-(1-methyl-o-carboranyl)methyl]benzaldehyde (2.13): A solution of compound
2.12 (0.994 g, 2.00 mmol) in THF (20 ml) under Argon was cooled to –78oC. n-BuLi (1.4
ml, 1.6 M in hexane) was added dropwise via syringe. After stirring the reaction mixture
for 30 minutes at –78o C, dry DMF (0.77 ml, 10.0 mmol) was slowly added. The
resulting yellow mixture was stirred at –78o C for 30 minutes and then warmed to 0o C
and stirred at this temperature for one hour. A 5% aqueous HCl solution was added until
the pH of the reaction mixture was between 2 and 3, and the final mixture stirred at room
temperature for 2 h. The aqueous layer was extracted 4 times with diethyl ether, the
organic fraction dried over anhydrous MgSO4 and the solvent evaporated under vacuum.
Purification by column chromatography (dichloromethane/petroleum ether 2:3), afforded
the title compound (0.632 g) in 70.9% yield, m.p. 205-207o C. MS m/e 446.4; 1H-NMR
(CDCl3) δ: 1.5-3.0 (br, 20H, BH), 2.20 (s, 6H, CH3), 3.55 (s, 4H, CH2), 7.30 (d, 1H, ArH), 7.67 (d, 2H, Ar-H), 10.03 (s, 1H, CHO).
Meso-tetra[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin

(2.14):

A

solution of aldehyde 2.13 (0.243 g, 0.54 mmol) and freshly distilled pyrrole (0.050 ml,
0.72 mmol) in dry dichloromethane (55 ml) was purged with Argon for 15 minutes. TFA
(0.03 ml, 0.377 mmol) was added and the final solution was stirred at room temperature
overnight (until complete disappearance of the starting aldehyde and formation of 2 new
spots by TLC). After oxidation with p-chloranil (0.102 g, 0.41 mmol) for 6 hours at room
temperature, the final reaction mixture was washed once with an aqueous saturated
solution of NaHCO3 and once with water, before being dried over anhydrous Na2SO4.
The residue obtained after removal of the solvent was purified by column
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chromatography using dichloromethane/petroleum ether 1:2 for elution. The porphyrin
fraction obtained was recrystallized from dichloromethane/methanol, to give 0.10 g (10%
yield) of the title compound, m.p. >300o C; MS m/e 1977.3 1H-NMR (d-TFA/CDCl3) δ
ppm: -0.80 (br, NH), 1.5-3.1 (br, 80H, BH), 2.31 (s, 24H, CH3), 3.91 (s, 16H, CH2), 7.72
(s, 4H, Ar-H), 8.33 (s, 8H, Ar-H), 8.74 (s, 8H, β-H). UV-Vis (CHCl3) λmax: 419 nm
(497,300), 509 (20,250), 543 (8,300), 588 (6,150), 642 (4,300).
Zn(II)-meso-tetra[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin (2.15): A
solution of porphyrin 2.14 (0.089 g, 0.20 mmol) , ZnCl2 (0.400 g) ,THF (10 ml) in
dichloromethane (100 ml) was stirred at room temperature for 3hrs.The solvent was
removed under vacuum and the reaction mixture was purified on a short silica column,
using dichloromethane/petether in 2:3 ratio for elution. Obtained 0.30g (14.7%) of the
title compound. HRMS m/e 2040.1766; 1H-NMR (CDCl3) δ ppm: 1.6-2.9 (br, 80H, BH),
2.20 (s, 24H, CH3), 3.75 (s, 16H, CH2), 7.43 (s, 4H, Ar-H), 8.01 (s, 8H, Ar-H), 8.85 (s,
8H, β-H). UV-Vis (CH2Cl2) λmax: 419nm (417,000), 547 (17,200), 582 (3,200).
Zn(II)-meso-tetra[bis-3,5-(1-methyl-nido-carboranyl)methylphenyl]porphyrin
tetrasodium salt (2.16): Porphyrin 2.15 (0.050 g,0.0245 mmol) was dissolved in a 3:1
mixture of pyridine and piperdine (4.0 ml), and stirred at room temperature in the dark
for 72 h, under argon . The solvent was completely removed under vacuum, the residue
redissolved in 40% aqueous acetone and passed slowly through a Dowex 50WX2-100
resin in the sodium form. The porphyrin fraction was collected, dried under vacuum,
redissolved in 70% aqueous acetone and again passed through the ion-exchange resin
.After removal of the solvent under vaccum , the octaanionic porphyrin was obtained as
pure crystalline solid. MS m/e 1953.66, 1H-NMR (CD3OCD3) δ ppm:-2.4(br, 8H, BH)
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1.6-2.9 (br, 72H, BH), 2.00 (s, 24H, CH3), 3.46 (s, 16H, CH2), 7.86 (s, 4H, Ar-H), 8.06
(s, 8H, Ar-H), 9.91 (s, 8H, β-H). UV-Vis (CH3OCH3) λmax: 425 nm (345,800), 556
(12,519), 595 (6,180).
Meso-tetra[bis-3,5-(1-methyl-nido-carboranyl)methylphenyl]porphyrin tetrasodium
salt (2.17): To the solution of Porphyrin 2.16 (0.016 g , 0.007 mmol) dissolved in 1ml
of methanol , 2ml of TFA was added and it was stirred for 30 min. Then add a drop of
H2SO4. The reaction mixture was dried under vacuum ,redissolved in methanol and TEA
was added until it was basic .The solvent was completely removed under vacuum , the
residue redissolved in 40 % aqueous acetone and slowly passed through a Dowex
50WX2-100 resin in the sodium form. The porphyrin fraction was collected, concentrated
under vacuum, redissolved in 70% aqueous acetone and again passed through the ionexchange resin. The solvent was removed under vaccum. MS m/e 1886.14 1H-NMR
(CD3OCD3) δ ppm:-2.4(br, 8H, BH) 1.6-2.9 (br, 72H, BH), 2.00 (s, 24H, CH3), 3.46 (s,
16H, CH2), 7.86 (s, 4H, Ar-H), 8.06 (s, 8H, Ar-H), 9.91 (s, 8H, β-H). UV-Vis
(CH3OCH3) λmax: 425 nm (327,700), 556 (12,519), 595 (6,180).
Cell Culture: Human glioblastoma T98G cells and cervical carcinoma HEp2 cells were
obtained from ATCC. The T98G cells and HEp2 cells were maintained in 50% of αMEM/advanced MEM supplemented with 5% FBS. Phosphate buffered saline (PBS),
Foetal Bovine Serum (FBS) and trypsin were purchased from Gibco, Cyquant reagent
from Molecular Probes, Triton X-100 from Calbiochem and lysosensor from Molecular
Probes. The microscopy was performed on a Zeiss Axiovert 200M inverted fluorescent
microscope fitted with a standard Texas Red and FITC filter sets (Chroma Technology
Corp.). The images were pseudo-colored with Adobe Photoshop® CS version 8.0.

60

Compounds 2.9, 2.16 and 2.17 were diluted in DMSO prior to being diluted into medium;
the final DMSO concentration never exceeded 1%. All medium solutions were filter
sterilized (22 µm pore size) prior to use. All the data from FLUOstar was analyzed using
Prism 3.0 graphing software.
Stock solutions of carboranylporphyrins H2TMCP and H2OCP were prepared by
weighing an exact amount of porphyrin in crystalline from and dissolving in 100%
DMSO; subsequent dilutions were done directly into the culture medium, just prior to
administration to cells. The porphyrin stocks were stored in 100% DMSO at 5 0C and
protected from exposure to light.
Cell Toxicity studies: Chinese hamster fibroblast cells V79 cells were sub cultured on 10
cm Petri dishes for 48 h in DMEM supplemented with 10% FBS and 1% penicillin –
streptococci solution. To prepare the incubation solution the appropriate amount of
porphyrin was dissolved in 250 µl of dimethylsulfoxide (DMSO) and diluted with
medium to obtain a 500 µM stock solution, which was then filtered through a sterile filter
(acetyl cellulose membrane, 22 µm pore size ). The cells were incubated for 24 h with 0
µM (standards) and 100-300 µM (total volume 2.5 ml) porphyrin concentrations. After
incubation, the cells were washed once with 5 ml sterile PBS and then harvested by
adding 200 µl of a 0.25% trypsine solution for 10 min at 37 C. DMEM (1.8 ml) was
added and the cells were gently aspirated, before 1 ml of the suspension was transferred
to a sterile centrifuge tube. After dilution to a total volume of 4 ml with DMEM the cells
were counted .Final dilutions were prepared allowing volumes of at at least 20 µl to
transfer 100 cells. For each incubation 100, 300 or 1000 cells were transferred to a 10 cm
petridish containing 10 ml DMEM to grow the clones for 6 to 7 days. After this period
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the adherent colonies were washed once with 5 ml PBS and fixed with 5 ml methanol for
10 min. Giemsa solution (5 ml) was then added to stain the clones for 40 min. The
Giemsa solution was removed, the clones washed with 3 ml of ethanol-water (7:3) and
finally, the colonies were counted and the percentage of survival determined by the
comparison to the standards. Each determination was performed in triplicate for each
porphyrin concentration.
Concentration-dependent cellular uptake: Human glioma T98G cells were cultured in
a costar 96 well plate at the concentration of 20000 cells/100 µL in each well. A 400 µM
solution of H2OCP 2.17 in DMSO diluted with α-MEM/advance medium, which was
filter sterilized. A two-fold dilution series was then prepared on the plate to give final
porphyrin concentrations of200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM,. 6.25 µM, 3.125
µM and 0 µM. After 3 h incubation time the cells were washed with PBS and 100 µl of
0.25% Triton X-100 in PBS was added to each of the wells. To obtain the standard graph
for H2OCP 2.17 a 20 µM solution of H2OCP 2.17 in 0.25% Triton X-100 was prepared
and used to make the dilution series of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0 µM. The
porphyrin fluorescence was measured on a FLUOstar plate reader using 570 nm
excitation and 650 nm emission filters. The standard curve for different cell numbers was
prepared by having 100000, 80000, 60000, 40000, 20000, 10000 and 0 number of cells in
the wells and incubated for 3 hours. The cell numbers were determined by adding 100
µl/well of a 2X stock solution of Cyquant reagent in PBS. The plate was read on the
FLUOstar plate reader using 480 nm excitation and 520 nm emission filters. The same
procedure as above was also followed for the concentration dependent uptake of the
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H2TCP. The fluorescence of the H2TMCP was read using the FLUOstar plate reader
using 540 nm excitation and 660 nm emission filters.
Time-dependent cellular uptake: Human T98G cells were subcultured as described
above. A stock solution of porphyrin 2.17 in DMSO was diluted with α-MEM/advance
medium to make a 10 µM stock solution, which was filter sterilized. After incubation of
the cells for 48 hrs the 10 µM stock solution was added and the cells incubated for 24, 8,
4, 2, 1 and 0 h periods. The cells were washed with PBS and 100 µl of 0.25% triton X100 in PBS was added to each of the wells. To obtain the standard graph for H2OCP 2.17
a 20 µM solution of H2OCP 2.17 in 0.25% triton X-100 was prepared and used to make
the dilution series of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0 µM. The porphyrin
fluorescence was measured on a FLUOstar plate reader using 570 nm excitation and 650
nm emission filters. The standard curve for different cell numbers was prepared by
having 100000, 80000, 60000, 40000, 20000, 10000 and 0 number of cells in the wells
and incubated for 3 hours. The cell numbers were determined by adding 100 µl/well of a
2X stock solution of Cyquant reagent in PBS. The same procedure was followed for the
time dependent uptake of H2TMCP and Zn-OCP. The fluorescence of H2TMCP
measured using on FLUOstar plate reader using 540 nm excitation and 660 nm emission
filters. The fluorescence of ZnOCP was also measured using 570 nm excitation and 650
nm emission filters.
Intracellular localization: T98G cells were seeded in a Lab-Tek II two chamber
coverglass system and incubated for 48 h. H2OCP 2.17 was added from a 25 mM stock
solution in DMSO to reach a final concentration of 10 µM. The cells were incubated in
the dark for 24 h, and then washed with drug-free medium three times to remove
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unbound porphyrin. The cells were then fed medium containing 50 mM HEPES pH 7.2
and examined using a Zeiss Axiovert 200M inverted fluorescence microscope fitted with
standard FITC and Texas Red filter sets. For co-localization experiments the tracer
compounds LysoSensor Green DND-189 and LysoTracker were used. The tracer
compounds were diluted into medium to reach a final concentration of 100 nM. This was
added to the H2OCP and incubated for 30 min. This was then washed with fresh hepes
medium and then viewed by microscopy. Fluorescence microscopy was also done for the
H2TMCP using the same equipment and the procedures as used for the H2OCP.
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Chapter 3
Synthesis of Tetra(4-nido-carboranylphenyl)porphyrin and Biological Evaluation of
the Tetra(4-nido-carboranylphenyl)porphyrin and
Tetra(carboranylphenyl)tetrabenzoporphyrin
3.1 Introduction
Boron containing porphyrins have been proposed for dual application in BNCT and PDT
treatment of malignant brain tumors because of their ability to be activated by both light
and low-energy neutrons.1 This has a significant enhancement of local control of the
disease by targeting different mechanisms of tumor cell destruction thus improving the
patient survival time. The low-energy neutron beam in BNCT can penetrate deep to reach
deep seated tumors whereas the short light penetration through the tissue to reach only
the superficial tumors is the disadvantage with PDT. The carboranylporphyrins with their
carborane cages can effectively deliver the required dosage of 15-20 µg of 10B/ gram of
tumor for BNCT. 2, 3 The tetrabenzoporphyrin with its carborane cages and the absorption
in the infrared region can act as a dual sensitizer both for PDT and BNCT. 4-7 The tetra(4nido-carboranylphenyl)porphyrin was synthesized using Lindsey’ conditions for the
synthesis of the meso-substituted carboranylporphyrins. The

10

B-enriched version of

tetra(4-nido-carboranylphenyl)porphyrin was also synthesized using
decaborane. Boron in its elemental form has only 20% of

10

B but a

10

B enriched

10

B-enriched have

nearly 100% of 10B.8 The derivatives of tetra(nido-carboranyl)porphyrins have also been
reported to interact with DNA, despite their negative charge and the bulkiness of the
carborane substituents.9 The formation of a complex between these anionic porphyrins
and DNA is either by the porphyrin inner core protonation or by noncovalent interactions.
They efficiently induced DNA damage when shined with light via photo-oxidation by
singlet oxygen.6
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Figure 3-1: Structures of the tetra(4-nido-carboranylphenyl)porphyrin 3.1 and the
tetra(carboranylphenyl)-tetrabenzoporphyrin 3.2

Tetrabenzoporhyrins(TBPs) belong to a family of π-extended porphyrins which contain
four β, β- fused benzene rings onto a porphyrin macrocycle. Consequently
tetrabenzoporphyrins have stronger absorptions in the red region of the optical spectrum,
where light penetration is considerably deeper, compared with porphyrins.10-13 Due to this
extension of conjugation TBPs displays unique optical, redox, chemical and physical
properties.14, 15, 16 They have numerous applications in non-linear optical materials, nearinfrared dyes, gas sensors, photosynthetic model compounds and as photosensitizers for
PDT of tumors.17-20

The tetrabenzoporphyrin 3.2 used for comparative biological

evaluation in this Chapter was synthesized from 4-carboranylbenzaldehyde and
butanopyrrole by Dr. Owendi Ongayi.13 This tetrabenzoporphyrin 3.2 and the tetra(4nido-carboranylphenyl)porphyrin 3.1 (synthesized by me) were evaluated for toxicity and
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uptake in tumor cells and also the intracellular localization of these porphyrins in the
tumor cells was also studied.21 The animal toxicity of these porphyrins was studied in
BALB/c mice. The animal toxicity studies were done in collaboration with Dr. David
Baker and Dr. Larry Lomax from the LSU School of Veterinary Medicine.
3.2 Photodynamic Therapy
Photodynamic therapy (PDT) is a binary method for the treatment of tumors that employs
light and a photosensitizer.22 A photosensitizer that specifically accumulates in the tumor
tissue in the presence of normal tissue is administered to the patient. Then the tumor and
the surrounding tissue are irradiated with visible light of a certain wavelength. The
excitation of the photosensitizer leads to the excitation energy being transferred to the
oxygen present in the cells. Thus, the triplet state oxygen is then transformed to the
highly reactive singlet oxygen, super oxide anion and hydroxyl radicals that cause
irreversible damage to the tumor cells.
A modified Jablonski diagram (without the vibrational levels) is shown in Figure 3-3, and
it outlines the mechanism of PDT.23 Photosensitizers with a stable electronic
configuration are in a singlet state at their ground state (S0). When irradiated with light of
appropriate wavelength it causes excitation of the photosensitizer to its singlet excited
state (S1). The singlet excited photosensitizer can either decay back to the ground state
with release of energy in form of fluorescence enabling identification of tumor tissue24 or
it can undergo a non-radiative process of inter-system crossing (ISC) thereby converting
the photosensitizer to a triplet excited state (T1). A good photosensitizer can go through a
spin-forbidden ISC pathway with very high efficiency and can then relax either
radiatively by phosphorence or non-radiatively by transferring its energy to another
molecule with a triplet ground state.
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Figure 3-2: Treatment of a cancer patient with PDT.25

Figure 3-3: Modified Jablonski diagram with the mechanism of PDT.26
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This allows interaction with molecular oxygen in its triplet ground state thus generating
highly cytotoxic species.27, 28
Photofrin and Visudyne are porphyrin derivative drugs approved by the FDA for the PDT
treatment of cancers (lung, digestive tract and genitourinary tract).29, 30 Porphyrins exhibit
many properties needed for an ideal PDT agent such as low dark toxicity, selective
accumulation in tumor tissue,31,

32, 33

high chemical stability, high affinity for serum

proteins, good pharmacokinetic properties, formation of stable complexes with metal
ions, fluorescent and strong absorbance in the visible region of the optical spectrum.1
Tetrabenzoporphyrins have an advantage over the porphyrins as PDT sensitizers as they
absorb strongly in the red region of the optical spectrum where the light penetration
through the tissue is higher.
In this Chapter I report the total synthesis of tetra(4-nido-carboranylphenyl)porphyrin
(H2TCP) which can be used as a BNCT agent.6, 34 The first total synthesis of the boron-10
enriched tetra(4-nido-carboranylphenyl)porphyrin was also performed. The

10

B-enriched

tetra(4-nido-carboranylphenyl)porphyrin is showing promising results in the BNCT
treatment of the mice being conducted at Ohio State University by Dr. Rolf Barth.35 It is
being further studied for applications in both PDT and BNCT by Dr. Giulio Jori at
University of Padova in Italy.
3.3 Results and Discussion
3.3.1 Synthesis of Tetra(4-nido-carboranylphenyl)porphyrin
The tetra(4-nido-carboranylphenyl)porphyrin 3.1 was synthesized in five steps from a
commercially available 4-ethnylbenzaldehyde 3.3 as shown in Scheme 3-1.6, 34 In the first
step the aldehyde functional group of the 4-ethnylbenzaldehyde 3.3 is protected using
ethanedithiol and BF3.OEt2 to produce 4-ethnylbenzyl(1,3-dithiane) 3.4.36
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Scheme 3-1: Synthesis of tetra(4-nido-carboranylphenyl)porphyrin 3.1
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The reaction was done in dry DCM followed by separation with 1:4 DCM: hexanes to
yield pure product 3.4 in 80% yield. The terminal alkyne of the 4-ethnylbenzyl(1,3dithiane) 3.4 is attacked with the Lewis base complex of decaborane37 to give the 4-(ocarboranyl)benzyl(1,3-dithiane) 3.5. The reaction was followed by acid-base workup to
remove the hydrogen formed during the reaction. This was then followed by separation
with 1:4 DCM: hexanes to yield pure product 3.5 in 67% yield. The de-protection of 4(o-carboranyl)benzyl(1,3-dithiane) 3.5 to get the 4-(o-carboranyl)benzaldehyde 3.6 was
done using Hg(ClO4)2 attack of the dithiane complex. 36 The precipitate formed at the end
of the reaction was washed with ethyl-ether and then passed through a silica gel column
with 1:4 DCM: petroleum ether to get pure product (without any starting material) in
86% yield. The 4-(o-carboranyl)benzaldehyde 3.6 was then condensed with freshly
distilled pyrrole using Lindsey’s conditions to yield the tetracarboranylporphyrinogen.
This

was

then

oxidized

with

p-chloranil

to

yield

crude

meso-tetra(4-(o-

carboranyl)phenyl)porphyrin 3.7 in 33% yield.38 The crude product was passed through
silica gel column using dichloromethane-petroleum ether 1:2 for elution of the pure
H2TCP. The fastest running fraction was collected and crystallized from methanol. Since
the closo carborane cages are hydrophobic the tetracarboranylporphyrin 3.7 was made
hydrophilic by the deboronation of a single boron atom from each of the four carborane
cages using a 3:1 mixture of pyridine and piperidine.39 This was then passed through a
DOWEX 50WX2-100 resin in the sodium form to exchange the piperidine on the nidocarboranylporphyrin

with

sodium

cations,

to

yield

meso-tetra[4-(nido-

carboranyl)phenyl]porphyrin tetra sodium salt 3.1 in 90% yield. This porphyrin 3.1 is
soluble in polar solvents such as methanol and water.
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The tetra(4-nido-carboranylphenyl)porphyrin was synthesized in order to do a
comparative biological study with the tetra(carboranylphenyl)tetrabenzoporphyrin 3.2 .
The novel 10B enriched version of the tetracarboranylporphyrin 3.1 was also synthesized
for BNCT analysis in mice. It is being studied in animals by the collaborative research
group.
The

10

B-enriched tetra(4-nido-carboranylphenyl)porphyrin since it is structurally similar

to the tetra(4-nido-carboranylphenyl)porphyrin was prepared using the same synthetic
methodology. The only difference in these porphyrins is the existence of enriched 10B in
the porphyrin which has 100% of 10B when compared to only 20 % of 10B in the tetra(4nido-carboranylphenyl)porphyrin 3.1. The only step that differs in the whole route is the
attack of the Lewis base of 10B-enriched decaborane instead of decaborane in the tetra(4nido-carboranylphenyl)porphyrin. The Lewis base of 10B-enriched decaborane attacks the
terminal alkyne of the 4-ethynlbenzyl(1,3-dithiane) to form the

10

B-enriched 4-(o-

carboranyl)benzaldehyde. This aldehyde in condensed with pyrrole under Lindsey’s
conditions to form the 10B-enriched tetra(4-closo-carboranylphenyl)porphyrin. This water
insoluble porphyrin was converted into the water soluble porphyrin by base degradation
of the carborane cages as described above followed by the exchange of the cations on an
ion exchange resin to yield the

10

B-enriched tetra(4-nido-carboranylphenyl)porphyrin in

35% overall yield.
The tetra(4-nido-carboranylphenyl)porphyrin 3.1 has four carborane cages attached
directly to the para positions of meso phenyl groups on the porphyrin macrocycle. The
closo-carboranylporphyrin 3.7 is non-polar and is soluble in organic solvents such as
DCM. This porphyrin 3.7 when converted into a tetra-anionic nido-carboranylporphyrin
3.1 becomes highly soluble in polar organic solvents, such as acetone, methanol, DMSO
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and in water. Porphyrin 3.1 has 36 boron atoms which make up 32% boron by weight,
making it a promising BNCT agent. The tetracarboranylporphyrin 3.1 was characterized
by MS-MALDI, 1H-NMR and UV-Vis spectroscopy.

Figure 3-4: MALDI-MS of the 10B-closo-H2TCP
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The 1H-NMR spectrum of 3.1 shows characteristic meso-phenyl protons as two doublets
at 7.66 and 7.97 ppm and the CH protons of the nido-carborane cages at 2.57 ppm. The
β-H on the pyrroles are present at 8.87 ppm. The BH protons on the open face of the
carborane cage form a broad singlet from -2.45 to -1.90 ppm whereas the remaining
protons on the carborane cages form a broad band from -0.8 to 2.40 ppm. The 1H-NMR
spectrum of the

10

B-enriched tetra(4-nido-carboranylphenyl)porphyrin showed similar

spectrum with slight downfield shifts. The UV-Vis spectra of tetracarboranylporphyrin
3.1 shows the characteristic Soret band at 420 nm and the four Q-bands forming an etiotype of spectrum (Figure 3-5).40 The compound 3.1 shows fluorescence emission at 670
nm with an excitation at 511 nm (Figure 3-6). As previously observed,7, 41 the presence of
the nido-carborane cages at the macrocycle periphery does not quench the fluorescence
characteristic of porphyrin-type compounds, The molecular structure of the Zn-complex
of porphyrin 3.7 exhibits a non-planar saddle conformation of the porphyrin macrocycle.

Figure 3-5: UV-Visible of tetrabenzoporphyrin 3.2 (full line) and
tetracarboranylporphyrin 3.1 (dashed line) at 5 µM concentration in methanol
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Figure 3-6: Fluorescence emission spectra of of tetrabenzoporphyrin 3.2 (full line) and
porphyrin 3.1 (dashed line) at 1 µM concentration in methanol (excitation at 532 and 511
nm, respectively)

3.3.2
Dark
Toxicity
of
Tetra(4-nido-carboranylphenyl)porphyrin
Tetra(carboranylphenyl)tetrabenzoporphyrin

and

The dark toxicity of the tetracarboranylporphyrin 3.1 and the tetrabezoporphyrin 3.2
towards V79 hampster fibroblast cells was evaluated using a MTT-based cell viability
assay.42 The results obtained are shown in Figure 3-8. The V79 fibroblast cells were
exposed to both porphyrins 3.1 and 3.2 up to concentrations of 300 µM and incubated for
24 hours at 370C. This was followed for chemical treatment of the viable V79 cells and
measurement of the absorbance at 570 nm. A similar experiment with varying
concentrations of DMSO which acts as a control for the cell growth, cell death and the
assay reagents was also done (Figure 3-7).
Figure 3-7 shows the dark toxicity of 0-10% concentrations of DMSO in the medium
clearly indicates that the DMSO is toxic to the V79 cells at concentrations above 1%.
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Figure 3-7: Darktoxicity of DMSO in the medium

Figure 3-8: Darktoxicity of tetrabenzoporphyrin 3.2 (full line) and porphyrin 3.1 (dashed
line) towards V79 cells using an MTT-based assay
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There is 50% cell viability (IC50=2.5% DMSO) at 2.5% DMSO in medium and above 5%
concentration it is almost 100% toxic.
Using the data from the DMSO toxicity the % DMSO in all cellular experiments never
exceeded 1%. The results obtained, as shown in Figure 3-8 indicate that both porphyrins
3.1 and 3.2 had no significant effect on the cell viability at concentrations up to 300 µM.
The tetrabenzoporphyrin 3.2 showed less toxicity towards V79 cells when compared with
tetracarboranylporphyrin 3.1.13 The dark toxicity of the tetrabenzoporphyrins has been
reported and these indicate that the benzene rings on the β-pyrrolic positions do not effect
the toxicity of the compound and that the porphyrin 3.2 is less toxic than the tetracarboranylporphyrin 3.1. In both the porphyrins 3.1 and 3.2 there is a consistent decrease
in the % cell viability with the concentration of the exogenous porphyrin until the
concentration reaches 37.5 µM. After concentration of 37.5 µM the % cell viability
reaches a plateau. The results are in agreement with previous studies,

7, 16, 43

that nido-

carboranylporphyrins and their derivatives have low dark cytotoxicity.
3.3.3 Cellular Uptake of Tetra(4-nido-carboranylphenyl)porphyrin
Tetra(carboranylphenyl)tetrabenzoporphyrin

and

The concentration-dependent uptake of H2TBP 3.2 and of the H2TCP 3.1 by human
glioblastoma T98 G cells were studied for a period of 3 hours and up to concentrations of
200 µM. This was followed by the solubulization of the T98G cells and the
measurements of the fluorescence intensity of the porphyrins 3.1 and 3.2. The
fluorescence of the H2TBP 3.2 was measured using 570 nm excitation and 720 nm
emission filters and the fluorescence of the H2TCP 3.1 was measured using 570 nm
excitation and 650 nm emission filters. The unknown cell numbers from the experiment
were measured for fluorescence using 480 nm excitation and 520 emission filters.
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Figure 3-9: Concentration-dependent uptake of H2TBP 3.2 (full line) and H2TCP 3.1
(dotted line) by human glioma T98G cells, after a 3 h time period.

The standards with the known cell numbers and the porphyrin concentrations of 3.1 and
3.2 were also calculated. The results obtained are shown in Figure 3-9. Figure 3-9 shows
consistent increases in the uptake of porphyrins 3.1 and 3.2 with the increase in the
concentration of the exogenous porphyrins.
The cellular uptake studies of the H2TBP 3.2 and the H2TCP 3.1 showed that both the
porphyrins are concentration dependent. The uptake of both the porphyrins 3.1 and 3.2 in
the T98G human glioblastoma cells increased with exogenous porphyrin concentration in
an almost linear fashion. At each corresponding concentration the H2TBP 3.2
accumulated within the T98G cells at significantly higher extent than porphyrin 3.1. The
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H2TBP 3.2 showed higher uptake (~ 30% more) in the cells than that of the H2TCP 3.1,
which may be the result of higher hydrophobicity of the H2TBP 3.2 compared with
H2TCP 3.1. The increased hydrophobic character of the H2TBP 3.2 is because of the four
β, β’-fused hydrophobic benzene rings. The nido-carboranylporphyrins are known to
accumulate more with the increasing hydrophobic character.44, 45
The time-dependent uptake of the 10 µM concentration of H2TBP 3.2 and H2TCP 3.1 by
T98G human glioblastoma cells was evaluated over different intervals of time up to 24
hours.

Figure 3-10: Time-dependent uptake of H2TBP 3.2 (full line) and H2TCP 3.1 (dashed
line) at 10 µM by human glioblastoma T98G cells.
The fluorescence intensities of both porphyrins and the cell numbers were measured
using the same filters as described before. The standards of the cell numbers and the
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porphyrins 3.1 and 3.2 were also evaluated. The results obtained are shown in Figure 310. The amounts of both the porphyins accumulated in T98G cells consistently increased
with time although the amount of tetrabenzoporphyrin 3.2 taken up by the T98G cells
was significantly more than the porphyrin 3.1 at each time point.
The cellular uptake of the porphyrins 3.1 and 3.2 into T98G cells was also found to be
time dependent. The H2TBP 3.2 and the H2TCP 3.1 accumulated in T98G cells over the
period of 24 hours. The H2TBP 3.2 was taken up faster and to a significantly higher
extent than the H2TCP 3.1 at all the time points studied. After 24 hours, the amount of
tetrabenzoporphyrin 3.2 accumulated was three times more than that of the
tetracarboranylporphyrin 3.1. The higher efficiency of uptake of H2TBP 3.2 might be
because of the higher hydrophobicity of this porphyrin.44, 45
3.3.4 Intracellular Localization of Tetra(4-nido-carboranylphenyl)porphyrin and
Tetra(carboranylphenyl)tetrabenzoporphyrin
The preferential sites of the localization of H2TBP 3.2 in human HEp 2 cells were
investigated using a Zeiss axiovert fluorescence microscope. First the HEp2 cells were
observed using the 63X/1.4 na plan-apochromatic oil immersion lens in the phasecontrast mode and then the cells were exposed to UV-visible light using a Texas-red
filter, DAPI filter and FITC filter to check for the background fluorescence of the HEp2
cells. The cells were then exposed to 50 µM concentration of H2TBP 3.2 for 24 hours and
then observed under fluorescence microscope using the Texas red filter. The fluorescence
emissions of the H2TBP 3.2 could be seen under the Texas red filter set. The HEp2 cells
were also checked for fluorescence using the DAPI and FITC filters since the organelle
trackers emit fluorescence signals under these filter sets. No fluorescence was seen when
observed under the DAPI filter and FITC filters. The localization pattern of the H2TBP
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3.2 in HEp2 cells was similar to the analyzed carboranylporphyrins that localized in the
cell lysosomes.

Figure 3-11: Intracellular localization of H2TBP 3.2 in HEp2 cells. A: Phase contrast; B:
H2TBP fluorescence; C: LysoSensor Green fluorescence; D: Overlay. Scale-20 µm.
So a co-localization experiment using lysosensor which preferentially localizes in the
lysosomes was used. After the incubation with the lysosensor for 30 min the HEp2 cells
were observed first under the Texas red filter for the fluorescence of the H2TBP 3.2 and
then using the same field of view the filter set was switched to the FITC under which the
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fluorescence from the lysosensor was observed. The images obtained were processed
using the Adobe Photoshop software.
Figure 3-11 A shows the HEp2 cells under phase contrast mode and Figure 3-11 B shows
the fluorescence of the H2TBP 3.2 under the Texas red filter, and it indicates a pattern
similar to that of localization in the cell lysosomes. This hypothesis was confirmed when
a co-localization experiment with lysosome specific probe lysosensor was done. Figures
3-11 C shows the fluorescence of the lysosensor in the lysosomes under the FITC filter.
When the figures showing the fluorescence of the lysosensor and the H2TBP fluorescence
were overlaid Figures 3-11 D was obtained which confirms that the two compounds
localize in the same organelle. The H2TBP 3.2 preferential localization in the cell
lysosomes of the HEp2 cells is the common pattern seen in negatively-charged
porphyrins which have affinity for the lysosomes because of their low internal pH.46, 47
The intracellular localization of the H2TCP 3.1 was also studied using the same methods
and instrumentation used for the H2TBP 3.2. The HEp2 cells were checked for
background

fluorescence

and

then

incubated

with

tetra(4-nido-

carboranylphenyl)porphyrin 3.1 for 4 hours at a concentration of 10 µM. After the
incubation the fluorescence of the H2TCP 3.1 through the Texas red filter was imaged and
the fluorescence in the DAPI and FITC filters was also checked. Since the pattern was
similar to that of the H2TBP 3.2 and other similar carboranylporphyrins, a co-localization
experiment to confirm the localization of the H2TCP 3.1 in the lysosomes was performed
using the lysosome specific biomarker lysosensor. The lysosensor in the lysosomes of the
HEp2 cells was imaged through the FITC filter. The same field of view was also used to
image the H2TCP 3.1 using the Texas red filter.
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Figure 3-12: Intracellular localization of H2TCP 3.1 in human HEp2 cells. A: Phase
contrast; B: Porphyrin fluorescence; C: LysoSensor Green fluorescence; D: Overlay.
Scale: 20 µm.

The H2TCP 3.1 was found to localize preferentially in the cell lysosomes of HEp2 cells.
Figure 3-12 A shows the phase contrast images of the HEp2 cells with the porphyrin 3.1
and the lysosensor. When imaged under the Texas red filter the fluorescence of porphyrin
3.1 can be clearly seen as the red dotted pattern in Figure 3-12 B. The filter set was
switched keeping the field of view constant and Figure 3-12 C under the FITC filter
shows the fluorescence of the lysosomes. Figures 3-12 B and 3-12 C were overlapped
using a imaging software to get Figure 3-12 D which clearly shows the yellow color
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formation indicating the exact overlap of the fluorescence from both porphyrin 3.1 and
the lysosensor, which are both localized in the lysosomes. These results are also in
accordance with the studies on anionic compounds such as H2TBP 3.2 which tend to
preferentially localize in the cell lysosomes because of their low internal pH. In contrast
cationic porphyrins often localize in the mitochondria because of the high
electrochemical potential of the inner mitochondrial membrane.48 The hydrophobicity
and the charge of the compounds play a vital role in the mode of entry into the cells and
their localization within the cell.
3.3.5 Animal Toxicity
The experiments were conducted in collaboration with Dr. David Baker and Dr. Larry
Lomax in the School of Veterinary Medicine. The animal toxicity experiments were
performed with the different concentrations of tetracarboranylporphyrin 3.1 and the
tetrabenzoporphyrin 3.2 on the BALB/c mice (4-6 weeks of age and weighing 12-24 g).
The experiments were started from a dosage of 20 mg / Kg and several different dosages
of 40 mg/kg, 80 mg/kg and 120 mg/kg were administered to the mice. The highest dosage
was 160 mg/kg. Tables 3-1 and 3-2 summarize the clinical data obtained for mice
receiving H2TBP 3.2 while Tables 3-3 and 3-4 summarize the results obtained with
tetracarboranylporphyrin 3.1. All mice received intra-peritoneal (i.p.) injections ranging
from volumes of 0.16 - 0.72 ml. The maximum dosage administered to groups 9 (mice
received H2TBP) and group 10 (mice received H2TCP) was 160 mg/kg, and represented
maximum saturation of 4 mg/ml. The highest dosage of 160 mg/kg was not toxic to mice
and also no serum chemistry changes occurred which were attributable to either
compound or vehicle administration, as suggested by the clinical and histologic values
shown in Tables 3-1 to 3-4.
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Both the porphyrins H2TCP 3.1 and H2TBP 3.2 did not show any signs of the toxicity in
the BALB/c mice. In the mice with H2TBP 3.2 (Tables 3-1 and 3-2) the glucose levels
were increased probably due to excitement and increased corticosteroid release. The
serum aspartate transaminase (AST) levels for some mice generally higher than normal
for some mice but were similar for most of the mice. They are not considered elevated
due to either H2TBP 3.2 or vehicle administration, because the increases were
inconsistent and the values found for mice in group 7 (receiving 120 mg/kg and 6%
Cremophore) had the lowest of the group means. This result suggests that muscle injury
or exertion may have contributed to increased AST levels in several of the mice. The
serum Alanine transaminase (ALT) levels were also similar and although higher than
normal in some mice. The elevations were not consistent among mice in the same
treatment groups so ALT levels are not considered elevated due to either H2TBP 3.2 or
vehicle administration and also the serum ALT is not specific for hepatocellular injury in
mice. The serum Alkaline Phosphatase (AP) levels although differed with each group but
were all within the normal range. The serum bilirubin levels also showed the same trend
and were all within the normal range. The serum Total Protein (TP) levels differed by
group, but were generally within the normal range. The TP levels for mice in group 9
were low probably because of the decrease in the albumin and globulin levels. The serum
albumin levels for mice in group 9 were lower than for other mice which might be
because of the decrease in the synthesis of the albumin as a result of hepatocellular
injury. However, tissue injury was not evident histopathologically. The low levels of
serum albumin can also result from the increased loss through renal or intestinal disease.
Likewise, the serum globulin levels were lower than expected, or lower than for control
mice in groups 1, 3, and 9.
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Table 3-1: Serum chemistry values for six BALB/c mice administered H2TBP 3.2
(groups 1, 3, 5) or 4% Cremophore (vehicle: group 11), by i.p. injection. The values
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows
with superscripts in common are not different from one another (p >0.05).

Group

1

3

5

11

Glucose
(mg/dl)

153.5a
(0.5)

219.5c
(5.5)

229.5c
(6.5)

188.0b
(10.0)

AST
(U/L)

177.5
(121.5)

455.5
(406.5)

454.5
(411.5)

83.0
(33.0)

ALT
(U/L)

151.5
(131.5)

96.5
(73.5)

120.0
(101.0)

31.0
(6.0)

AP
(U/L)

189.5a,c
(0.5)

201.0b,c
(31.0)

138.0a
(8.0)

128.5a
(1.5)

Bilirubin
(mg/dl)

0.15
(0.05)

0.20
(0.10)

0.20
(0)

0.15
(0.05)

Total Prot.
(g/dl)

4.65
(0.15)

4.7
(0)

5.1
(0)

4.5
(0.20)

Albumin
(g/dl)

2.85
(0.05)

2.8
(0)

2.75
(0.05)

2.75
(0.15)

Globulin
(g/dl)

1.8a
(0.1)

1.9a
(0)

2.35b
(0.05)

2.3b
(0.1)

BUN
(mg/dl)

28.0
(0)

27.0
(3.0)

25.5
(2.5)

29.0
(1.0)
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Table 3-2: Serum chemistry values for four BALB/c mice administered H2TBP 3.2
(groups 7, 9) or 6% Cremophore (vehicle: group 12), by i.p. injection. The values
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows
with superscripts in common are not different from one another (p >0.05).

Group

7

9

12

Glucose
(mg/dl)

224.5
(12.5)

172.0
(19.0)

206.5
(12.5)

AST
(U/L)

73.0
(16.0)

498.0
(410.0)

774.0
(149.0)

ALT
(U/L)

29.0
(3.0)

206.0
(176.0)

411.5
(123.5)

AP
(U/L)

161.0a
(3.0)

223.5b
(0.5)

169.0c
(0)

Bilirubin
(mg/dl)

0.2
(0)

0.25
(0.05)

0.2
(0)

Total Prot.
(g/dl)

5.1a
(0.10)

4.35b
(0.05)

4.65b
(0.05)

Albumin
(g/dl)

2.75a
(0.05)

2.4b
(0)

2.6c
(0)

Globulin
(g/dl)

2.35a
(0.05)

1.95b
(0.05)

2.05b
(0.05)

BUN
(mg/dl)

15.5a,b
(1.5)

22.5b,c
(2.5)

33.0c
(3.0)
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The serum Blood Urine Nitrogen (BUN) levels differed among groups, but were also
within normal limits. All the above finding for the mice administered with H2TBP 3.2
likely represented a stress response in the mice due to the injections and not due to the
compound 3.2 or vehicle effects.
For the tetracarboranylporphyrin 3.1 (Tables 3-3 and 3-4) the glucose levels showed a
increased probably due to excitement and increased corticosteroid release. The serum
AST levels were all similar and although slightly higher than normal, they were not
considered elevated due to either H2TCP 3.1 or vehicle administration; muscle injury or
exertion could also contributed to increased AST levels in several mice. The serum ALT
levels were all similar in most of the mice but some mice exhibited higher than normal
levels. These elevations in the ALT levels were not attributed to either 3.1 or vehicle
administration since they were not consistent among mice in the same treatment groups.
The serum AP and bilirubin levels were within the normal range. The serum TP levels
were also within the normal range, and only differed from controls for group 2, which
received the lowest dose (20 mg/kg) of H2TCP 3.1. The serum albumin levels were all
similar and within normal limits. Likewise, serum globulin levels were only lower than
vehicle controls for mice in group 2, which received the lowest porphyrin dose. The
serum BUN levels differed among groups but were also within normal limits. These
results were likely due to stress-related increases in serum corticosteroid levels. The
histopathologic examination revealed no lesions attributable to compound administration.
Extramedullary hematopoiesis was observed in all mice, and may represent mild levels of
stress, typical of mice under manipulative experimental conditions.
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Table 3-3: Serum chemistry values for six BALB/c mice administered porphyrin 3.1
(groups 2, 4, 6) or 4% Cremophore (vehicle: group 11), by i.p. injection. The values
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows
with superscripts in common are not different from one another (p >0.05).

Group

2

4

6

11

Glucose
(mg/dl)

159.5a
(1.5)

188.0b
(3.0)

153.5a
(9.5)

188.0b
(10.0)

AST
(U/L)

146.0
(36.0)

202.0
(144.0)

258.0
(181.0)

83.0
(33.0)

ALT
(U/L)

98.5
(25.5)

94.0
(71.0)

340.0
(296.0)

31.0
(6.0)

AP
(U/L)

167.5a
(11.5)

132.0a,c
(4.0)

148.0a,c
(12.0)

128.5b,c
(1.5)

Bilirubin
(mg/dl)

0.2
(0.10)

0.25
(0.05)

0.25
(0.05)

0.15
(0.05)

Total Prot.
(g/dl)

4.3a
(0.10)

4.6a,b
(0)

5.0b
(0.10)

4.5b
(0.20)

Albumin
(g/dl)

2.7
(0)

2.6
(0)

2.8
(0)

2.75
(0.15)

Globulin
(g/dl)

1.6a
(0.1)

2.0b
(0)

2.35c
(0.05)

2.3c
(0.1)

BUN
(mg/dl)

26.5
(2.5)

24.0
(2.0)

27.5
(1.5)

29.0
(1.0)
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Table 3-4: Serum chemistry values for four BALB/c mice administered porphyrin 3.1
(groups 8, 10) or 6% Cremophore (vehicle: group 12), by i.p. injection. The values
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows
with superscripts in common are not different from one another (p >0.05).

Group

8

10

12

Glucose
(mg/dl)

239.5
(8.5)

214.5
(29.5)

206.5
(12.5)

AST
(U/L)

774.0
(690.0)

981.0
(837.0)

774.0
(149.0)

ALT
(U/L)

968.0
(918.0)

1096.0
(1041.0)

411.5
(123.5)

AP
(U/L)

160.5a
(7.5)

223.0b
(7.0)

169.0a
(0)

Bilirubin
(mg/dl)

0.25
(0.05)

0.25
(0.05)

0.2
(0)

Total Prot.
(g/dl)

4.9
(0.20)

4.5
(0.20)

4.65
(0.05)

Albumin
(g/dl)

2.5
(0.1)

2.5
(0.1)

2.6
(0)

Globulin
(g/dl)

2.4a
(0.1)

2.0b
(0.1)

2.05a,b
(0.05)

BUN
(mg/dl)

16.0a
(3.0)

25.5a,b
(2.5)

33.0b
(3.0)
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The non-toxicity of H2TBP 3.2 and porphyrin 3.1 up to a dose of 160 mg/kg is in
agreement with the low toxicity reported for hydrophobic carboranylporphyrins.49,

50

However, compounds 3.2 and 3.1 are significantly less toxic than other negatively
charged carboranyl-containing porphyrins, such as BOPP, MnBOPP, BTPP, NiNTCP-H,
ZnDPE and NiDPE.50-53 Our results show, as previously observed, that nidocarboranylporphyrins can have low mice toxicities, even at high compound doses often
required to achieve therapeutic levels of boron in tumors.50, 54, 55
3.4 Conclusions
The synthesis of promising BNCT agents tetra(4-nido-carboranylphenyl)porphyrin and
the novel

10

B enriched tetra(4-nido-carboranylphenyl)porphyrin were achieved in good

overall yields. The biological properties of tetra(4-nido-carboranylphenyl)porphyrin 3.1
was compared with tetra(carboranylphenyl)-tetrabenzoporphyrin 3.2 using various
techniques. Both porphyrins 3.1 and 3.2 have 36 boron atoms and 32% boron by weight
for tetra(4-nido-carboranylphenyl)porphyrin 3.1 and 27% boron by weight for
tetra(carboranylphenyl)-tetrabenzoporphyrin

3.2.

The

tetra(carboranylphenyl)-

tetrabenzoporphyrin 3.2 showed less toxicity towards V79 cells than the tetra(4-nidocarboranylphenyl)porphyrin 3.1 though both porphyrins showed CS50 > 300 µM. The
tetra(carboranylphenyl)-tetrabenzoporphyrin showed higher uptake in T98G cells than
the tetra(4-nido-carboranylphenyl)porphyrin because of the better hydrophobicity
resulting from its four β,β’-porphyrin fused benzene rings. Both porphyrins 3.1 and 3.2
localized in the lysosomes of HEp2 cells when observed under a fluorescence
microscope. The porphyrins 3.1 and 3.2 also showed very low levels of toxicity in
BALB/c mice. Both porphyrins 3.1 and 3.2 were not toxic even at the high dose of 160
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mg/kg administered in a single intra peritoneal injection. Since no clinical, biochemical,
or histo-pathological effects were observed in the BALB/c mice it cannot be attributed to
the administration of H2TBP 3.2, porphyrin 3.1 or the vehicle used. The results suggest
that the H2TCP 3.1 is a good BNCT agent and the H2TBP 3.2 is an excellent dual
sensitizer for BNCT and PDT.
3.5 Experimentals
Chemistry: Commercially available starting materials were purchased from SigmaAldrich and used without further purification.

10

B-decaborane and decaborane were

purchased from Katchem. All solvents were purchased from Fisher Scientific (HPLC
grade) and either directly used or dried and distilled according to literature procedures.
Silica gel 60 (70-230 mesh, Merck) and alumina grade III (70-230 mesh ASTM) were
used for column chromatography. Analytical thin-layer chromatography (TLC) was
performed on Merck 60 F254 silica gel (precoated sheets, 0.2 mm thick). 1H-NMR
spectra were obtained using a Bruker DPX 250 MHz or 300 MHz spectrometer; chemical
shifts are expressed in ppm relative to TMS (0 ppm). Electronic absorption spectra were
measured on a Perkin Elmer Lambda 35 UV-Vis spectrophotometer and fluorescence
spectra on a Perkin Elmer LS55 instrument. Low resolution MS analyses were conducted
at the LSU Mass Spectrometry Facility on a Bruker Prolix III MALDI-TOF mass
spectrometer, and the HRMS were conducted at the Ohio State University Mass
Spectrometry and Proteomics Facility. Melting points were measured on an
Electrothermal MEL-TEMP instrument.
p-Ethynylbenzyl(1,3-dithiane) (3.4): To a solution of 4-ethynylbenzaldehyde (3.3) (6.0
g, 46.15 mmol) and 1,2-ethanedithiol (5.0 g, 53.09 mmol) was added BF3·OEt2 (0.654 g,
4.62 mmol) at 0 oC under argon. The mixture was stirred at 25 oC for 15 m then washed
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once with a 10% aqueous NaOH solution, and once with aqueous saturated solution of
NaCl. The organic layer was dried over anhydrous Na2SO4 and the solvent removed
under vacuum. The resulting residue was purified by column chromatography
(dichloromethane-hexane, 1:4) to give 7. 0 g (80%) of p-ethynylbenzyl(1,3 – dithiane).
M.p: 68-69 oC; MS (EI) m/z 206.0 (M+); 1H-NMR (CDCl3) δ ppm: 3.09 (s, 1H, CH),
3.38 and 3.52 (m, 2H each, CH2CH2), 5.62 (s, 1H, SCH), 7.42 (d, 2H, Ar-H), 7.48(d, 2H,
Ar-H).
p-(o-Carboranyl)benzyl(1,3-dithiane) (3.5): A solution of decacarborane (3.0 g, 24.59
m mol) and ethyl sulfide (5.0 g, 55.44 mmol) in dry toluene (50 ml) were combined in a
schlenk tube and was heated at 40 oC for 3 h and then at 60 oC for 2 h. The solution was
allowed to cool to 25 oC and to this mixture p-ethynylbenzyl(1,3-dithiane) (3.4) (5.0g,
24.26 mmol) in dry toluene (10 ml) was added and the final mixture was stirred at 80 oC
for 3 days. After cooling to room temperature, the mixture was concentrated under
vacuum and the oily residue was dissolved in methanol (250 ml) and heated to reflux for
1 h (until no hydrogen was liberated). At room temperature, 2.5 mL of HCl (50%
aqueous) was added dropwise and the mixture was again refluxed for another 30 m until
the evolution of hydrogen was complete. After cooling to 25 oC, the mixture was diluted
with ethanol and excess ethylsulfide was removed by ethanol-ethylsulfide co-distillation.
The resulting residue was reduced in volume under vacuum and dissolved in 100 mL of
benzene (CAUTION) at 5 oC. This was followed by addition of 100 mL of cold 10%
aqueous NaOH solution, and the mixture was allowed to stir vigorously for 15 m. The
organic layer was separated and washed twice with water and dried over anhydrous
Na2SO4. After removing the solvent under vacuum, the residue was purified by column
chromatography (eluting with dichloromethane-hexane, 1:4) to give 5.2 g (67%) of the
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title compound. M.p: 118-119 oC; MS (EI) m/z 324.1 (M+); 1H-NMR (CDCl3) δ ppm: 1.6
- 3.3 (br, 10H, BH), 3.36 and 3.47 (m, 2H each, CH2CH2), 3.94 (br s, 1H, o-carboraneCH), 5.59 (s, 1H, SCH), 7.40 (d, 2H, Ar-H), 7.46 (d, 2H, Ar-H).
10

B-enriched p-(o-Carboranyl)benzyl(1,3-dithiane): MS (EI) m/z 316.2 (M+), 1H-NMR

(CDCl3) δ ppm: 1.6 - 3.3 (br, 10H, BH), 3.41 and 3.53 (m, 2H each, CH2CH2), 3.97 (br s,
1H, o-carborane-CH), 5.62 (s, 1H, SCH), 7.44(d, 2H, Ar-H), 7.50 (d, 2H, Ar-H).
4-(o-Carboranyl)benzaldehyde (3.6): p-(o-Carboranyl)benzyl(1,3-dithiane) (3.5) (2.5 g,
1.28 mmol) was dissolved in 5% aqueous THF (15 ml) and a solution of Hg(ClO4)2 (6.25
g , 15.65 mmol) in 5 % aqueous THF (10 ml) under argon was added dropwise. The final
mixture was stirred at room temperature for 15 m, before being filtered and the
precipitate was washed three times with 25 ml diethyl ether. The filtrate was washed once
with an aqueous saturated solution of Na2CO3 and with water before being dried over
anhydrous Na2SO4. The solvent was removed under vacuum and purified by column
chromatography (elution with dichloromethane-petroleum ether 1:4) to give the title
compound (1.6 g, 85%) and recovering the rest of the starting material. M.p: 172-173 oC;
MS (EI) m/z 248.2 (M+); 1H-NMR (CDCl3) δ ppm: 1.5 - 3.3 (br, 10H), 4.08 (br, 1H, ocarborane-CH), 7.69 (d, 2H, Ar-H), 7.90 (d, 2H, Ar-H), 10.07 (s, 1H, CHO).
10

B-enriched 4-(o-Carboranyl)benzaldehyde: MS (EI) m/z 240.5 (M+); 1H-NMR

(CDCl3) δ ppm: 1.5 - 3.3 (br, 10H), 4.07 (br, 1H, o-carborane-CH), 7.68 (d, 2H, Ar-H),
7.88 (d, 2H, Ar-H), 10.07 (s, 1H, CHO).
Meso-Tetra[4-(closo-carboranyl)phenyl]porphyrin (3.7): A solution of aldehyde (3.6)
(1.05 g, 4.23 mmol) and freshly distilled pyrrole (0.03 ml, 4.32 mmol) in dry
dichloromethane (430 ml) was purged with argon for 30 m. TFA (0.2 ml, 2.52 mmol)
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was added to the solution and the mixture was stirred at room temperature under argon
for 24 h. After addition of p-chloranil (0.780 g, 3.14 mmol) the final mixture was stirred
at room temperature for 3 h. The solution was concentrated under vacuum to 300 ml, and
then washed once with aqueous saturated NaHCO3 and once with water before being
dried over anhydrous Na2SO4. After evaporation of the solvent under vacuum the
resulting residue was purified by column chromatography (elution with dichloromethanepetroleum ether 1:2) and the fastest running fraction was collected and recrystallized
from methanol, yielding 0.407 g (33% yield) of the title compound. M.p: > 300oC; MS
(MALDI) m/z 1183.02 (M+); 1H-NMR (CDCl3) δ ppm: -2.89 (br, 2H, NH), 1.7 - 3.4 (br,
40H, BH), 4.28 (br s, 4H, o-carborane-CH ), 7.90 (d, 8H, Ar-H), 8.18 (d 8H, Ar-H), 8.78
(s, 8H, β-H ). UV-Vis (CHCl3) λmax: 418 nm (ε 469,000), 514 (18,200), 550 (8,600), 590
(6,200) and 646 (4,900).
10

B-enriched meso-Tetra[4-(closo-carboranyl)phenyl]porphyrin: MS (MALDI) m/z

1151.07 (M+); 1H-NMR (CDCl3) δ ppm: -2.84 (br, 2H, NH), 1.7 - 3.4 (br, 40H, BH), 4.32
(br s, 4H, o-carborane-CH ), 7.92(d, 8H, Ar-H), 8.20 (d 8H, Ar-H), 8.82 (s, 8H, β-H ).
Meso-Tetra[4-(nido-carboranyl)phenyl]porphyrin tetra sodium salt (3.1):Porphyrin
3.7 (0.050 g, 0.0423mmol) was dissolved in a 3:1 mixture of pyridine and piperdine (4.0
ml), and stirred at room temperature in the dark for 36 h, under argon. The solvent was
completely removed under vaccum, the residue redissolved in 40% aqueous acetone and
passed slowly through a Dowex 50WX2-100 resin in the sodium form. The porphyrin
fraction was collected, dried under vaccum, redissolved in 70% aqueous acetone and
again passed through the ion-exchange resin. After removal of the solvent under vaccum,
the tetraanionic porphyrin was recrystallized from methanol-diethyl ether yielding pure
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crystalline solid. Mp>300 oC MS m/e 1229.84, 1H-NMR (CD3OCD3) δ ppm: -2.78 (s ,
2H, NH) , -2.45 to –1.90 (br, 4H, BH), 0.8–2.40 (br, 32H, BH), 2.57 ( br s, 4H, nidocarborane-CH), 7.66 (d, 8H, ArH), 7.97 (d, 8H, ArH), 8.87 (s, 8H, β-H). UV-Vis
(CH3OCH3) λmax: 420 nm (ε 302,900), 516 (11,600), 554 (10,600), 594 (3,300),
650(4,900).
10

B-enriched meso-Tetra[4-(nido-carboranyl)phenyl]porphyrin tetra sodium salt:

MS m/e 1201.56, 1H-NMR (CD3OCD3) δ ppm: -2.70 (s , 2H, NH) , -2.45 to –1.90 (br,
4H, BH), 0.8–2.40 (br, 32H, BH), 2.61 ( br s, 4H, nido-carborane-CH), 7.72 (d, 8H,
ArH), 8.02 (d, 8H, ArH), 8.93 (s, 8H, β-H).
Cell Culture: Cervical carcinoma HEp2 cells, human glioblastoma T98G cells and V79
hampster fibroblast cells were obtained from ATCC. All the cells were maintained in
50% of α-MEM/advanced MEM supplemented with 5% fetal bovine serum (FBS).
Phosphate buffered saline (PBS), FBS and trypsin were purchased from Gibco, Cyquant
reagent and Lysosensor from Molecular Probes, and Triton X-100 from Calbiochem.
Microscopy was performed on a Zeiss Axiovert 200M inverted fluorescent microscope
fitted with a standard Texas Red and FITC filter sets (Chroma Technology Corp.). The
images were aquired with a Zeiss Axiocam MRM CCD camera fitted to the microscope
and pseudo-colored with Adobe Photoshop® CS version 8.0. Compounds 3.1 and 3.2
were dissolved in DMSO (Sigma-Aldrich) prior to being diluted into cell medium; the
final DMSO concentration never exceeded 1%. All medium solutions were filter
sterilized (22 µm pore size) prior to use. All data obtained from the FLUOstar plate
reader was analyzed using Prism 3.0 graphing software.
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Dark toxicity: V79 hampster fibroblast cells were sub-cultured on 96-well plates at the
concentration of 2,000 cells/100 µl α-MEM/advance medium per well, and incubated for
48 h. A stock solution of 300 µm of H2TBP 3.2 was prepared. The overall DMSO
concentration never exceeded the 1% limit. Serial dilutions were done starting with the
300 µm and achieving different concentrations of 150 µM, 75 µM, 37.5 µM, 18.75 µM,
9.375 µM and 0 µM. Various concentrations of DMSO in medium ( 10%, 5%, 2.5%,
1.25%, 0.625%, 0.3125% and 0%) were also done as a control for cell growth, cell death
and the assay reagents. 0.4% of saponin in PBS was also added to some wells to mimic
the 100% cell death. The plate was incubated for 24 h. After incubation the porphyrin
compound was removed and the cells were washed twice with fresh medium and a 100 µl
of fresh medium was added to each of the wells. To each of the wells a 15 µl of the pierce
cell titer 96 MTT substrate was added and then incubated for 4 h. After the 4 h a stop
solution was added and incubated for a hour at 37 0C or at room temperature overnight.
This solubilizes the insoluble colored precipitate that forms when MTT is reduced by
living cells. The absorbance was read on FLUOstar plate reader at 570 nm. The
calculation and normalization of the data was done using prism 3.0 graphing software.
The same procedure was also used for the dark toxicity of the H2TCP 3.1. Both the
experiments were done simultaneously under the same conditions.
Concentration-dependent cellular uptake: Human T98G cells were sub-cultured on
96-well plates at the concentration of 10,000 cells/100 µl α-MEM/advance medium per
well, and incubated for 48 h. A 200 µM stock solution of H2TBP 3.2 in DMSO was
diluted with α-MEM/advance medium and added to the cells to achieve H2TBP final
concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.125 and 0 µM. After incubation for 3 h,
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the medium was removed, the cells washed with PBS, and 100 µl of 0.25% Triton X-100
in PBS added to each well. A H2TBP 3.2 standard graph was obtained by diluting a 10
µM stock solution in 0.25% Triton X-100 in PBS to achieve 10, 5, 2.5, 1.25, 0.625,
0.3125 and 0 µM H2TBP concentrations. The H2TBP fluorescence of the known and the
unknown concentrations was measured on a FLUOstar plate reader using 570 nm
excitation and 720 nm emission filters. The standard curve for different cell numbers was
obtained by placing 100000, 80000, 60000, 40000, 20000, 10000 and 0 cells in the wells
followed by incubation for 3 h. The known cell numbers for the standard graph and the
unknown cell numbers from the experiment were determined by first adding 100 µl/well
of 5 µM stock solution of Cyquant reagent in PBS and then reading the plate on the
FLUOstar plate reader using 480 nm excitation and 520 emission filters. The data
obtained from the FLUOstar plate reader were analyzed and interpreted using Prism 3.0
software. The same procedure was followed for determination of the concentrationdependent cellular uptake of porphyrin 3.1, using 570 nm excitation and 650 nm emission
filters.
Time-dependent cellular uptake: Human T98G cells were sub-cultured on 96-well
plates at the concentration of 10,000 cells/100 µl of α-MEM/advance medium per well,
and incubated for 48 h. A filter sterilized 10 µM stock solution of H2TBP 3.2 in 1%
DMSO/medium was added and the cells incubated for 24, 16, 8, 4, 2, 1, 0.5 and 0 h. The
medium was removed, the cells washed with PBS and 100 µL of 0.25% Triton X-100 in
PBS was added to each well. A H2TBP 3.2 standard graph was obtained by diluting a 10
µM stock solution in 0.25% Triton X-100 in PBS to achieve 10, 5, 2.5, 1.25, 0.625,
0.3125 and 0 µM H2TBP concentrations. The fluorescence of the known and unknown
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concentrations of H2TBP 3.2 was measured on a FLUOstar plate reader using 570 nm
excitation and 720 nm emission filters. The standard curve for different cell numbers was
obtained by placing 100000, 80000, 60000, 40000, 20000, 10000 and 0 cells in the wells
followed by incubation for 3 h. The known cell numbers for the standard graph and the
unknown cell numbers from the experiment were determined by first adding 100 µl/well
of 5 µM stock solution of Cyquant reagent in PBS and then reading the plate on the
FLUOstar plate reader using 480 nm excitation and 520 emission filters. The data
obtained from the FLUOstar plate reader were analyzed and interpreted using Prism 3.0
software. The same procedure was followed for determination of the time dependent
cellular uptake of porphyrin 3.1, using 570 nm excitation and 650 nm emission filters.
Intracellular localization: Human HEp2 cells were sub-cultured on Lab-Tek II chamber
cover slips with α-MEM/advance medium for 48 h. H2TBP 3.2 was added to each
chamber to reach a final concentration of 50 µM. The cells were incubated for 24 h,
washed twice with 50 mM HEPES to remove unbound H2TBP 3.2, new medium
containing 50 mM HEPES pH 7.4 was added and the cells examined immediately by
fluorescence microscopy. For the co-localization experiments 100 nM of Lysosensor was
added to the TBP-containing cells 30 minutes before the completion of the incubation
time. The same techniques and instrumentation were used for the evaluation of the intracellular localization of the tetra(4-nido-carboranylphenyl)porphyrin. The human HEp2
cells were incubated with tetra(4-nido-carboranylphenyl)porphyrin for period of 4 hours
at a concentration of 10 µM.
Animal Toxicity: The mice were obtained from the breeding colony operated by the
Division of Laboratory Animal Medicine, School of Veterinary Medicine, Louisiana
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State University. The animal studies were conducted under an animal use protocol
approved by the LSU Institutional Animal Care and Use Committee, fully accredited by
the Association for the Assessment and Accreditation of Laboratory Animal Care,
International. Twelve groups of two BALB/c mice, 4-6 weeks of age and weighing 12-24
g (mean = 19 g), were used; among these 8 were female and 16 were male. Mice in
groups 1, 3, 5, 7, and 9 were administered H2TBP 3.2 once via i.p. injection, at increasing
dosages: group 1 (20 mg/kg of a 2 mg/ml solution), group 3 (40 mg/kg of a 2 mg/ml
solution), group 5 (80 mg/kg of a 4 mg/ml solution), group 7 (120 mg/kg of a 4 mg/ml
solution), and group 9 (160 mg/kg of a 4 mg/ml solution). Mice in groups 2, 4, 6, 8, and
10 were administered porphyrin 3.1 once via i.p. injection at increasing dosages: group 2
(20 mg/kg of a 2 mg/ml solution), group 4 (40 mg/kg of a 2 mg/ml solution), group 6 (80
mg/kg of a 4 mg/ml solution), group 8 (120 mg/kg of a 4 mg/ml solution), and group 10
(160 mg/kg of a 4 mg/ml solution). Two groups of mice served as vehicle controls. Mice
in group 11 received sterile 4% Cremophor EL (Fluka) in PBS and served as controls for
mice receiving 20, 40, and 80 mg/kg compound while mice in group 12 received 6%
Cremophor EL and served as controls for mice receiving 120 and 160 mg/kg compound.
For each compound, groups were dosed sequentially and each group evaluated daily
for signs of toxicity, including hunched posture, rough hair coat, and decreased
responsiveness. Mice were anesthetized with CO2 48 h after compound administration,
and blood collected by cardiocentesis for clinical chemistry evaluation. The serum
chemistry performed included glucose, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (AP), bilirubin, total protein (TP),
albumin, globulin, and blood urea nitrogen (BUN). The mice were exsanguinated and a
necropsy performed. Tissues, including lung, kidney, thymus, heart, harderian gland,
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spleen, stomach, small intestine and colon were fixed in 10% neutral buffered formalin.
The fixed tissues were processed and examined by a board-certified pathologist.
Statistical Analyses: The clinical chemistry values were compared using the Number
Cruncher Statistical System software (NCSS, Kaysville, UT). Variables of interest were
statistically evaluated for group effect, using One-Way ANOVA. When the overall F
statistic was significant (p < 0.05), the Fisher’s Least Significant Differences test was
performed to compare the groups. Significant differences existed when p > 0.05.
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Chapter 4
Syntheses of Tetra[4-(1-hydroxyethyl-carboranyl)methylphenyl]porphyrin, Tetra[4(1-triethyleneglycol-carboranyl)methylphenyl]porphyrin and Tetra[4-(1aminomethyl-carboranyl)phenyl]porphyrin
4.1 Introduction
In BNCT, the boron-containing compound must be non-toxic and selectively accumulate
in cancerous tissue while delivering therapeutic amounts of boron, ~15-30 µg of 10B/g of
boron to tumors.1 Hydrophilicity is one of the most important properties in the
development of an ideal BNCT agent. Both disodium mercapto-closo-dodecarborate
(BSH) and 4-dihydroxyborylphenylalanine (BPA), the only two drugs currently
undergoing BNCT clinical trails show low selectivity for tumor cells and low retention
times in tumors. Furthermore BSH is chemically unstable which increases its toxicity and
BPA has only low percentage of boron by weight so a large dose is necessary for
effective BNCT.2 Since BSH and BPA are not ideal BNCT agent several other BPA
derivatives and boron containing amino acids as well as non amino acids were
synthesized and evaluated.3-7 Highly water soluble carbohydrate derivatives of BSH and
other boron containing sugars were synthesized and evaluated both in vivo and in vitro.814

These compounds showed low toxicity and uptake in tumor cells. Various other boron-

containing analogues of biologically active compounds such as amino acids,15 peptides,16
nucleosides/nucleotides,17 phospholipids,18 liposomes,19 and monoclonal and bispecific
antibodies20, 21 have been synthesized and studied.
Of all the compounds analysed porphyrins and their analogues are of great interest in the
field of development of the ideal BNCT agent.22 The tetraphenylporphyrins (TPPs)
contain four phenyl groups, typically on the meso positions of the porphyrin ring.23 The
tetraphenylporphyrins can be made water soluble by the functionalization of its phenyl
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rings with sulfonates,24 carboxylates25 and caboranes.26 Porphyrins have been synthesized
with the carborane groups attached to the phenyl ring of tetraphenylporphyrin.27 The
porphyrin macrocycle and the closo-carborane cages are hydrophobic. Amide, ester, or
urea bonds which are more hydrophilic than carbon-carbon likages have been used to link
the carboranes to the porphyrins.28-31 The disadvantage with using such hydrophilic
groups is that they have a propensity to hydrolyze while being transported in vivo
resulting in the release of the hydrophobic carboranes. This causes failure in delivering
therapeutic amounts of boron to the tumor tissue. Therefore there has been significant
effort to increase the water solubility of carboranylporphyrins while not compromising
their chemical stability. Vicente and coworkers solved this problem of stability by
synthesizing a series of carboranylporphyrins with a water-soluble carborane linked to
the meso phenyl groups on the porphyrin macrocycle with hydrophobic carbon-carbon
linkages.32 These stable methylene linkages are not prone to hydrolysis or any other
chemical attack in the in vivo environment. The series of carboranylporphyrins
synthesized by Vicente and coworkers are water soluble by the degradation of the
carborane cages in to a nido-carborane cage.33 The closo carborane cage can be degraded
with the use of base to remove one boron and form a negative charge on the carborane
cage. These anionic carboranylporphyrins localize in the tumor cells and they also have
low in vivo and in vitro toxicity.34 Water-soluble compounds can be directly dissolved in
saline and administered to patients whereas the hydrophobic compounds have to be
solubilized using liposomes or Chremophor EL which can alter the pharmacokinetics of
these compounds.35-40 A suitable balance between the hydrophilicity of the nidocarborane cages and the hydrophobicity of the porphyrin macrocycle is essential to
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achieve high specificity towards tumors and high tumor to blood and to normal tissue
boron ratios.
The target carboranylporphyrins synthesized and discussed in this Chapter are watersoluble not by degradation of the carborane cages but by the functionalization of the
carboranes

with

water-solubilizing

groups

such

as

amine,

hydroxy

and

polyethyleneglycol groups (see Figure 4-1).
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Figure 4-1: Structures of the target porphyrins 4.1, 4.2 and 4.3
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In the preceding Chapters I have synthesized water-soluble carboranylporphyrins which
were negatively charged and localized selectively in the lysosomes of tumor cells
because.41,

42

It has been reported that cationic porphyrins localize in the mitochondria

because of the high electrochemical potential of the inner mitochondrial membrane.43
Neutral, anionic and cationic porphyrins display multiple localization sites within the
cells which can effectively result in the tumor cell destruction. The uptake of the
carboranylporphyrins is dependent on the nature of the peripheral side chains,
hydrophobic character, charge, molecular weight, acid-base properties, aggregation state,
charge/mass ratio and also the charge distribution. All the neutral carboranylporphyrins
synthesized have 40 boron atoms each and 28%-32% of boron by weight. So they can
potentially deliver therapeutic amounts of boron-10 to the tumors. The target porphyrins
have stable methylene linkages between the meso phenyl group of the porphyrin
macrocycle and the carborane. The carboranes are functionalized only on the ortho
position of the carborane and so these functional groups will not be hydrolyzed nor
attacked by other chemicals inducing loss of the carboranes before they reach the tumor.
Another advantage of these functionalized carboranylporphyrins is that they are highly
fluorescent and this enables the detection of tumor cells using fluorescence microscopy,44
and the determination of 10B localization in tumors and surrounding tissues. Intracellular
boron distribution and quantification play an important role in determining the dose and
length of neutron radiation, as well as the success of the BNCT treatment.
4.2 Synthesis of Tetra[4-(1-hydroxyethyl-carboranyl)methylphenyl]porphyrin
Porphyrin 4.1 is prepared from commercially available 4-butyn-1-ol 4.4 as indicated in
Scheme 4-1. The terminal alcohol of 4.4 was protected with t-butyldimethylsilylchloride
(TBDMSCl) 45 to produce protected alkyne 4.5. The 4-butyn-1-ol was dissolved in DMF
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with imidazole and to this mixture t-butyldimethylsilylchloride was added and the final
solution heated at 500C. The mixture was neutralized and purified on a silica gel column
using 1:9 ratio of ethyl acetate/hexane to give an oily clear liquid in 60% yield. The 4butyne-1-ol 4.4 was first protected with t-butyldimethylsilylchloride before it was reacted
with decaborane since acetylenes containing hydroxyl groups fail to give the carborane
products. Since the hydroxyl groups on the acetylenes can degrade the carborane cages,
the protected alkyne 4.5 was reacted with a Lewis base complex of ethylsulfide and
decaborane46 in dry toluene to give the substituted protected siloxy carborane 4.6. The
reaction was done in a schlenk tube for three days and after the reaction was finished it
was worked up first with methanol, followed by 50% aqueous HCl and 10% aqueous
NaOH. The product formed was purified by filtration through a silica column with 1:9
ethyl acetate and hexane. The ratio of ethyl acetate was slowly increased until it finally
reached 6:4 (ethyl acetate: hexane) and a pure product was obtained. This unknown
product 4.8 was characterized by 1H-NMR and mass spectroscopy. This reaction did not
work since the tertiary butyldimethylsiloxy group got cleaved from the alcohol functional
group during the acidic work up of the reaction. The protected alcohol 4.5 was stirred
with a solution of aqueous HCl to confirm the acidic cleavage of the siloxy protecting
group. The acidic workup was avoided in later experiments. The reaction was then
worked up by refluxing with methanol and ethanol to remove the hydrogen formed in the
reaction. The reaction mixture was dissolved in methanol and passed through a silica
column with ethyl acetate and hexane in 1:9 ratio. The pure white solid product carborane
4.6 was formed in 60% yield. The reaction was repeated in a larger scale under same
conditions to yield pure product in large amounts.
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Scheme 4-1: Synthesis of compound 4.7
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Scheme 4-2: Synthesis of unwanted compound 4.8
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Carborane 4.6 was characterized by 1H-NMR and mass spectrometry. The 1H-NMR
clearly shows the characteristic broad singlet proton of the CH on the ortho carborane at
4.01 ppm, as seen in Figure 4-2. This is a shift from the proton on the terminal alkyne 4.5
at 1.95 ppm (triplet). The methyl and butyl protons on the silyl group are at 0.06 and 0.9
ppm respectively because of the low electro negativity of the silyl group. The methylene
linkages appear as triplets at 2.44 and 3.72 ppm.

Figure 4-2: 1H-NMR of the carborane 4.6 in CDCl3 at 300 MHz
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The most acidic proton of carborane 4.6 is deprotonated with n-BuLi and a SN2 reaction
of the 4-bromobenzylbromide resulted in a carborane-substituted bromobenzene 4.7.47
The SN2 reaction between carborane 4.6 and the 4-bromobenzylbromide was successful
after multiple trials with various solvents and different reaction conditions. Initially dry
DME was used as a solvent and the reaction was stirred at room temperature. This did not
yield any product even after various trials with the temperatures. DME probably was
hampering the formation of anion on the carborane 4.6.

Figure 4-3: 1H-NMR of carborane 4.7 in CDCl3 at 300 MHz
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In a Dry THF the anion of carborane 4.6 was formed with n-BuLi and the SN2 reaction of
this anion with 4-bromobenzylbromide gave the carborane-substituted bromo benzene 4.7
in 75% yield. A catalytic amount of LiI was added to expedite the reaction by the
substitution of the benzyl bromide with iodine which is a better leaving group. The
impure product was purified on a silica gel column with DCM and petroleum ether 1:9.
The pure product was characterized by 1H-NMR, in which the aromatic protons are
downfield at 7.05 and 7.47 ppm, as seen in Figure 4-3. The protons of the methylene
carbon linking the carborane to the bromobenzene are a singlet at 3.48 ppm. There is a
slight shift in the methylene protons from 2.44 and 3.72 ppm (in carborane 4.6) to 2.56
and 3.82 ppm in compound 4.7. The synthesis of the aldehyde 4.10 is the key step in the
formation of the target porphyrin 4.1. The synthesis of aldehyde 4.10 was first attempted
by reacting compound 4.7 with n-BuLi, which involves a Li-Br exchange, followed by
reaction with DMF and acid hydrolysis with 2N HCl.

Br

CHO

O Si

n-BuLI
DMF

O Si

Aq. HCl

4.7

4.10

Scheme 4-3: Failed synthesis of aldehyde 4.10
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This reaction did not work probably due to the non formation of the Li complex of
compound 4.7 and the failure of the attack towards the DMF.48 The acid hydrolysis might
have also cleaved the acid labile tertiary butyl dimethyl siloxy group. This was tried
many times with similar results.
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Scheme 4-4: Synthesis of aldehyde 4.10
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Therefore a different route to aldehyde 4.10, as described in Scheme 4-4, was followed.
In

the

first

step

4-(bromomethyl)-benzonitrile

4.11

was

reduced

with

diisobutylaluminium hydride followed by 10% H2SO4 to form pure white crystals of 4(bromomethyl)-benzaldehyde 4.12 in 90% yield.49 After the formation of aldehyde 4.12
the formyl functional group was protected with 1, 2-ethane dithiol in the presence of
BF3.Et2O.50 After stirring for 15 min at room temperature it was neutralized with 10%
NaOH and then washed with brine and water to get the pure white product 4(bromomethyl)benzenedithiane 4.13 without further need for purification in 63% yield.
The aldehyde functional group is protected to prevent a secondary reaction between the
aldehyde and the anion of the carborane in the next step. The anion of carborane 4.6
generated by addition of n-BuLi in dry THF undergoes an SN2 reaction with 4(bromomethyl)-benzyldithioethylene 4.13. LiI in THF was added with dithiane 4.13 and
the reaction mixture immediately changed to a red color from a colorless solution. After
overnight stirring at room temperature the color changed to yellow and at this point it was
quenched with water and worked up with ethyl ether. The impure product was passed
through a silica gel column using DCM: Hexane 2:3 for elution to give the pure product
carborane-substituted benzyldithiane 4.14 in 48% yield. The formation of the product
carboranyl benzyldithiane 4.14 was confirmed by

1

H-NMR which shows the

disappearance of the broad singlet of the ortho proton on the carborane cage of 4.6. The
two methylene linkage between the carborane and the silyl group shift from 2.44 and 3.72
ppm in silylcarborane 4.6 to 2.57 ppm and 3.82 ppm in compound 4.14. The aromatic
doublet protons on the benzene ring appear at 7.12 and 7.50 ppm and a singlet benzyl
proton at 5.63 ppm. The hydrogens on the dithiane form multiplets at 3.36 ppm and 3.49
ppm. The methylene linkage between the carborane and the benzene appears at 3.52 ppm.
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Deprotection of compound 4.1451 was done using two equivalents of mercury perchlorate
in 5% aqueous THF. The reaction was completed in 15 min, the reaction mixture was
filtered and the filtrate was washed with ethyl ether and then washed with an aqueous
solution of Na2CO3 and water. The final product was purified with 1:9 ratio of DCM:
hexane to recover some of the starting material 4.14.

Figure 4-4: 1H-NMR of the carborane 4.10 in CDCl3 at 300 MHz
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Scheme 4-5: Synthesis of porphyrin 4.1
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In the 1H-NMR spectrum the characteristic aldehyde peak was seen at 10.03 ppm with
the disappearance of the dithiane and benzyl protons, as seen in Figure 4-4. The
methylene linkage between the carborane and the benzaldehyde shifted from 3.49 ppm to
3.61 ppm. The aromatic protons shifted slightly downfield from 7.12 and 7.50 ppm in
compound 4.14 to 7.36 ppm and 7.86 ppm in 4.10. Aldehyde 4.10 will then be condensed
with pyrrole using Lindsey’s conditions to form the porphyrinogen which was oxidized
with p-chloranil to form porphyrin 4.15.52
The cleavage of the t-butyldimethylsiloxy groups to form the meso-tetra[4-(1hyrdoxyethyl-carboranyl)methylphenyl]porphyrin 4.1 will be accomplished using TFA.53
4.3 Synthesis of Tetra[4-(1-triethylenegycol-carboranyl)methylphenyl]porphyrin
The aim of this work was to develop a synthetic route to a poly(ethyleneglycol)
containing carboranylporphyrin 4.2 which is thought to be more water-soluble than the
meso-tetra[4-(1-hydroxyethyl-carboranyl)methylphenyl]porphyrin

4.1.

Both

these

porphyrins will be synthesized and evaluated for biological importance. The
amphiphilicity of porphyrins 4.1 and 4.2 will also be evaluated and compared.
Tri(ethyleneglycol)monomethylethertosylate

4.17

was

easily

made

from

tri(ethyleneglycol)monomethylether 4.16 by substitution of the primary alcohol with the
tosyl group using anhydrous pyridine as a solvent. The product was formed in 90% yield
and was used in the next step without further purification. This was followed by iodine
substitution

on

tri(ethyleneglycol)monomethylethertosylate

4.17

to

form

the

tri(ethyleneglycol)monomethylether iodide 4.18.54 The tosylate group was substituted
with iodide by refluxing the tosylate 4.17 and NaI in butanone. The resulting crude
product was purified with 10:1 ratio of DCM/ethyl acetate in silica gel. Both these steps
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resulted in formation of the tri(ethyleneglycol)monomethylether iodide 4.18 in overall
yield of 92%.
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Scheme 4-6: Failed synthesis of dithianecarborane 4.22
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The 1H-NMR confirmed the structure of the iodide 4.18 with methylene protons of the
polyethylene gycol forming multiplets at 3.27, 3.57, 3.66 and 3.77 ppm, as seen in Figure
4-5. The methyl protons formed a singlet at 3.40 ppm.

Figure 4-5: 1H-NMR of the iodide 4.18 in CDCl3 at 300 MHz
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This polyethylenegycol iodine 4.18 was then reacted with 4-(o-carboranyl)benzyl(1,3dithiane) 4.21. The 4-(o-carboranyl) benzyl (1, 3-dithiane) 4.21 was synthesized in three
steps from commercially available 4-ethynylbenzaldehyde 4.19.34 Firstly the formyl
functional group of the 4-ethynylbenzaldehyde 4.19 was protected using ethanedithiol
and BF3.OEt2 to produce 4-ethynylbenzyl(1,3-dithiane) 4.20. The resulting residue was
purified by column chromatography (dichloromethane-hexane, 1:4) to give 80% of pethynylbenzyl(1,3–dithiane) 4.20. The 1H-NMR confirmed the structure of product 4.20
with the disappearance of the aldehyde peak at 10.03 ppm in the starting material 4.19
and the appearance of the methylene protons of the dithiane 4.20 at 3.38 and 3.52 ppm.
The presence of the benzyl proton at 5.62 ppm also confirms the structure of the product.
The proton on the terminal alkyne appears at 3.09 ppm and the aromatic protons at 7.42
and 7.48 ppm. The terminal alkyne of the 4-ethynlbenzyl(1,3-dithiane) 4.20 is then
attacked with ethyl sulfide complex of decaborane in dry toluene to give the 4-(ocarboranyl)benzyl(1,3-dithiane) 4.21. The three day reaction was followed by an acidic
and basic workup to give a crude product which was purified by passing through a silica
gel column with dichloromethane and hexane (1:4) used for elution. The yield of the
reaction was 67%. The 1H-NMR of the product 4.21 dissolved in deuterated chloroform
shows the ten boron protons of the carborane cage between 1.6 - 3.3 ppm. The
characteristic ortho-carborane CH proton forms a broad singlet at 3.94 ppm, as seen in
Figure 4-6. The idea of this route was to generate an anion on the ortho carborane
position of the 4-(o-carboranyl)benzyl(1,3-dithiane) 4.21 with one equivalence of n-BuLi
and then do an SN2 reaction with the tri(ethyleneglycol)monomethylether iodide 4.18 to
obtain the wanted product carborane 4.22. But this reaction did not work probably
because of the deprotonation of the acidic proton on the benzylic position of the 4-(o124

carboranyl) benzyl(1,3-dithiane) 4.21 rather than the proton on the ortho carborane
position.

Figure 4-6: 1H-NMR of the carborane 4.21 in CDCl3 at 300 MHz
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The pKa values of both the acidic protons on carborane 4.21 are nearly similar and this
might be reason for the competitive de-protonation within the same molecule.
An alternate shorter route for the formation of porphyrin 4.2 where there is a methylene
linkage between the carborane and the phenyl ring was tried. This route was inspired by
the polyethylene glycol carborane 4.25 synthesized by Bregadze and coworkers.55
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Scheme 4-7: Synthesis of polyethyleneglycol carborane 4.25 by Bregadze and coworkers
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Bregadze and coworkers synthesized the polyethylene glycol carborane 4.25 in five steps
from tri(ethyleneglycol)monomethylether 4.16. According to their route as shown in
Scheme 4-7 compound 4.16 was converted to iodide 4.18 in two steps with a total yield
of 92%. Compound 4.18 was then reacted with lithium trimethylsilylacetylenide to give
trimethylsilylacetylenide

4.23.

The

compound

4.23

was

then

treated

with

tetrabutylammonium fluoride to remove the trimethylsilyl group and forms the acetylene
4.24 in 86% yield. The acetylene was then reacted with decaborane in acetonitrile to give
the carborane 4.25.
They also reacted o-carborane with the tri(ethyleneglycol)monomethyl iodide 4.18 and
they obtained a disubstituted derivative and an unsubstituted o-carborane in a 2:1:1 ratio.
Taking

a

cue

from

this

failure

of

the

reaction

of

o-carborane

with

tri(ethyleneglycol)monomethyl iodide 4.18 to give reasonable yields I decided to try the
reaction between the tri(ethyleneglycol)monomethyl iodide 4.18 obtained from the
previous reaction and commercially available o-carborane. o-carboranes always gives
low yields due to disproportionation. In the first attempt o-carborane was dissolved in dry
THF, the mixture was cooled to 00C and one equivalent of n-BuLi was added at this
temperature. After stirring this mixture for 1.5 hours one equivalent of the
tri(ethyleneglycol)monomethyl iodide 4.18 in dry THF was added. This was warmed to
room temperature and after stirring overnight the reaction was worked up. This reaction
did not result in any product. So a second trial was done wherein the reaction was carried
out at -78 0C instead of 0 0C. The reaction resulted in the formation of polyethylene
glycol carborane 4.25 after separation from the o-carborane with 1:3 ratio of ethyl
acetate/hexane on a silica gel column. Since the tosylate group is a better leaving group
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than the iodide group the idea to react the tri(ethyleneglycol)monomethylether tosylate
4.17 with the o-carborane was tried.
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Scheme 4-8: Synthesis of polyethyleneglycol carborane 4.25

In this route tri(ethyleneglycol)monomethylether tosylate 4.17 was used to form the
tri(ethyleneglycol)monomethylethercarborane 4.25 by the SN2 reaction of the anion of ocarborane with the tosylate 4.17. Since tosylate group is a better leaving group than
iodide, the compound 4.17 was used instead of the compound 4.18. Two hours after the
addition of the n-BuLi at 0 0C the tri(ethyleneglycol)monomethylether tosylate 4.17 was
added and the resulting mixture warmed to room temperature and stirred overnight. The
crude mixture was separated using DCM for elution on a silica gel column. All the non
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polar impurities eluted first and the product was eluted using 4:2 ratio of ethyl
acetate/hexane. The yield of this reaction was 65% and this route also resulted in
recovery of o-carborane in minor yields. This reaction has to have just equal equivalents
of n-BuLi and the tri(ethyleneglycol)monomethylethertosylate 4.17 as there are two
acidic hydrogens on the o-carborane and this might result in the formation of the
unwanted disubstituted derivative.

Figure 4-7: 1H-NMR of the carborane 4.25 in CDCl3 at 300 MHz
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The 1H-NMR confirms the formation of the product carborane 4.25, as seen in Figure 47. The hydrogens attached to the borons form a broad peak extending from 1.00 to 3.42
ppm. The methylene attached directly to the carborane forms a triplet at 2.55 ppm and the
remaining ten hydrogens on the polyethylene chain form a multiplet from 3.56 to 3.66
ppm. The methyl on the terminal methoxy shows up as a singlet at 3.41 ppm and the
characteristic hydrogen attached to the ortho position of the carborane forms a broad
singlet at 4.25 ppm. The reaction to form the carborane 4.25 from the tosylate 4.17 was
scaled up and good yields were obtained. The next step was to do an SN2 substitution on
the 4-(bromomethyl)benzenedithiane 4.13 with the carborane 4.25. The idea was to
generate the anion of the carborane 4.25 and attack at the bromide leaving group on
compound 4.13. In the first attempt to form the target compound 4.27 the carborane in
dry THF was cooled to 0 0C and the n-BuLi was added followed by the addition of the
dithiane 4.13 and LiI at -200C. After overnight stirring at room temperature the reaction
mixture did not yield any product. The only isolated products were the starting materials.
So the next trial was done wherein the n-BuLi was added to the carborane 4.25 in THF at
-78 0C. This mixture was warmed to -20 0C and then the LiI and the dithiane 4.13 in dry
THF were added. The resulting mixture was warmed to room temperature and stirred
overnight. This method did not yield the wanted product but some substituted carboranes
without the polyethyleneglycol were obtained. An alternate reaction was done using
commercially

available

4-bromobenzylbromide

4.26

instead

of

the

4-

(bromomethyl)benzenedithiane 4.13. 4-bromobenzylbromide 4.26 was used because of
its easy availability compared with 4-(bromomethyl)benzenedithiane 4.13 which is
obtained in a two step reaction. I also wanted to confirm the generation of the anion of
the carborane 4.25 using various solvents and temperature conditions.
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Scheme 4-9: Synthesis of carboranes 4.27 and 4.28

In the first attempt to the mixture of the carborane 4.25 in dry THF at 0 0C and then after
2 hours the temperature was reduced to -200C and the LiI and the 4-bromobenzylbromide
were added and the reaction mixture stirred overnight at room temperature. This reaction
failed to yield any product as tried before with the same conditions as dithiane 4.13. The
reaction between the 4-bromobenzyl bromide and the carborane 4.25 was also tried at -78
0

C with the same results as before. So the reaction was tried at -30 to -40 0C.
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Scheme 4-10: Synthesis of polyethyleneglycol porphyrin 4.2
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The carborane 4.25 in dry THF was cooled to -40 0C and then n-BuLi was added
followed by addition of the 4-bromobenzyl bromide 4.26 at -20 0C. The reaction mixture
was warmed to room temperature and stirred overnight. This resulted in the formation of
some wanted product 4.28. Further purification has to be done in order to characterize the
compound 4.28. The same method will also be applied for the formation of the dithiane
4.27. When either the dithiane 4.27 or compound 4.28 is formed they will be converted to
the aldehyde 4.29. The dithiane 4.27 can be de-protected with mercury perchlorate to
form aldehyde 4.29. The compound 4.28 can be reacted with dry DMF to form aldehyde
4.29. The aldehyde 4.29 can than be condensed with distilled pyrrole in the presence of
catalytic amount of TFA to form the porphyrinogen which can than be oxidized with pchloranil to form the tetra(1-triethyleneglycol-carboranyl)phenyl porphyrin 4.2 (Scheme
4-10). The total synthesis and characterization of both the tetra(1-triethyleneglycolcarboranyl)methylphenyl

porphyrin

4.2

and

the

tetra(1-hydroxyethyl-

caboranyl)methylphenylporphyrin 4.1 will be done. The biological evaluation of both
these porphyrins will also be done.
4.4 Synthesis of Tetra[4-(1-aminomethyl-carboranyl)phenyl]porphyrin
Porphyrin 4.37 was synthesized from commercially available 3-bromopropyne 4.31 as
shown in Scheme 4-11. The propargyl bromide 4.31 was reacted with the potassium salt
of phthlamide 4.30 to form the substituted product N-propargyl phthlamide 4.32. The
solvent acetone was removed after 12 hours and the residue purified by column
chromatography to give compound 4.32 in 80% yield. The 1H-NMR confirmed the
formation of the product with the appearance of the aromatic doublet protons at 7.75 ppm
and 7.87 ppm.
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Scheme 4-11: Synthesis of dithianecarborane 4.35
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Compound 4.32 was then coupled with 4-bromobenzaldehyde in the presence of
Pd(OAc)2 and triphenyl-phosphine in anhydrous triethyl amine to form the 4(propynepthalamide)benzaldehyde 4.33.56 The final mixture obtained after 8 hours of
reflux was purified with 1:4 ratios of DCM/hexanes on a silica gel column. The yield of
this reaction was 78%. The appearance of the aromatic protons of the benzylaldehyde at
7.26 ppm and 7.58 ppm and also the characteristic aldehyde peak in the 1H-NMR at 9.98
ppm confirms the formation of product 4.33. The aldehyde 4.33 was then protected with
ethylene dithiol to form 4-(phthlamidopropnyl)-phenyl 1, 2-dithiane 4.34. The dark
yellow mixture obtained was purified to obtain compound 4.34 in 83% yield. The
disappearance of the aldehyde peak at 9.98 ppm and the appearance of the dithiane peaks
in the 1H-NMR spectrum at 3.34 ppm and 3.47 ppm confirm the formation of compound
4.34. The alkyne on the dithiane 4.34 was complexed with the Lewis base of the
decaborane in dry toluene to form the carborane 4.35. After workup the crude product
was purified on a silica gel column with 4:1 ratio of DCM/hexanes to form the 4-(1methylphthlamidocarborane)-phenyl 1, 2-dithiane 4.35 in 60% yield. The 1H-NMR
confirmed the formation of product 4.35. The methylene linkage between the nitrogen
and the alkyne in compound 4.34 appears at 4.68 ppm and it shifts upfield to 3.90 ppm in
the carborane 4.35. All the aromatic and dithiane protons in the starting compound 4.34
show similar 1H-NMR shifts in the carborane 4.35. The B-H protons on the carborane
form a broad peak from 1.9 ppm to 3.4 ppm. The 4-(1-methylphthlamidocarborane)phenyl 1, 2-dithiane 4.35 was then deprotected with mercury (II) perchlorate to form
aldehyde 4.36. The procedure used was similar to that of the previous methods of
deprotection of the dithiane. The yield of this reaction was 75%.
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Figure 4-8: 1H-NMR of aldehyde 4.36 in CDCl3 at 300 MHz

The disappearance of the dithiane peaks and the appearance of the aldehyde peak at 10.10
ppm confirm the formation of compound 4.36, as seen in Figure 4-8. Condensation of
aldehyde 4.36 with pyrrole in the presence of TFA under Lindsey conditions, as
previously described, produced target porphyrin 4.37 in very low yields. After the
disappearance of the aldehyde 4.36 in the reaction mixture p-chloranil was added to
oxidize the porphyrinogen to the porphyrin 4.37.
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Figure 4-9: UV-visible of the porphyrin 4.37 in DCM

Figure 4-10: Fluorescence of porphyrin 4.37
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The separation was also very difficult as multiple products were formed. The first
separation was done using 7:3 of DCM/hexane on a silica gel column. This separation
yielded three major fractions. The fastest running fraction was further purified with 3:7 of
ethyl acetate and petroleum ether to get the product porphyrin 4.37 in the low yield of
3%. The porphyrin 4.37 shows the characteristic UV-Visible spectrum of mesosubstituted porphyrins with an etio-type of spectrum (Figure 4-9). Figure 4-10 shows the
fluorescence emission spectrum of porphyrin 4.37 with emission peaks at 605 and 651
nm when excited at 419 nm. Because of the low yields obtained further steps of
deprotection of the pthalamide with hydrazine to form the amino porphyrin 4.3 were not
performed. 57
4.5 Conclusions and Future Work
The aldehyde 4.10 required for the synthesis for the meso-tetra[4-(1-hydroxyethylcarboranyl)methylphenyl]porphyrin was formed in high yields and the further reaction
for the formation of porphyrin 4.1 will be performed. The polyethyleneglycol carborane
4.25 was formed in high yields and in fewer steps than the proposed route by Bregadze
and coworkers. The further reaction to form the aldehyde 4.25 and the eventual reaction
to form the meso-tetra[4-(1-triethyleneglycolcarboranyl)methylphenyl]porphyrin 4.2 will
be done. The synthesis of the porphyrin 4.37 is completed and further characterization of
porphyrin 4.37 will be done. The yield of the reaction in the formation of the porphyrin
4.37 will also be increased and then the last step of deprotection to form the meso-tetra[4(1-aminomethyl-carboranyl)methylphenyl]porphyrin 4.3 will also be performed.
The synthesis of all these novel porphyrins will be followed by biological evaluation of
these porphyrins in tumor cells. The porphyrins will be tested for their toxicity towards
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normal cells in culture and also in mice. The uptake concentration and the intracellular
localization of these porphyrins in tumor cells will also be evaluated.
4.6 Experimentals
Chemistry: Commercially available starting materials were purchased from SigmaAldrich and used without further purification. All solvents were purchased from Fisher
Scientific (HPLC grade) and either directly used or dried and distilled according to
literature procedures. Silica gel 60 (70-230 mesh, Merck) and alumina grade III (70-230
mesh ASTM) were used for column chromatography. Analytical thin-layer
chromatography (TLC) was performed on Merck 60 F254 silica gel (precoated sheets, 0.2
mm thick). 1H-NMR spectra were obtained using a Bruker DPX 250 MHz or 300 MHz
spectrometer; chemical shifts are expressed in ppm relative to TMS (0 ppm). Electronic
absorption spectra were measured on a Perkin Elmer Lambda 35 UV-Vis
spectrophotometer and fluorescence spectra on a Perkin Elmer LS55 instrument. Low
resolution MS analyses were conducted at the LSU Mass Spectrometry Facility on a
Bruker Prolix III MALDI-TOF mass spectrometer, and the HRMS were conducted at the
Ohio State University Mass Spectrometry and Proteomics Facility. Melting points were
measured on an Electrothermal MEL-TEMP instrument.
4-(tert-butyldimethylsiloxy) 1-butyne (4.5): To a solution of 3-butyne-1-ol 4.4 (2 gm,
28.5 mmol) and imidazole (5.8 gm, 85 mmol) in DMF (25 ml) was added TBDMSCl (6.5
gms, 42.75 mmol) at room temperature. The reaction mixture was heated at 50 0C for 4.5
hrs and quenched with aqueous NaHCO3 and then extracted with ethyl ether .The organic
extracts were washed with water , brine and then dried over Na2SO4 concentrated under
vacuum to get a oily liquid .It was separated using N-hexane to get a clear oily liquid in
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60% yield (3 gm). MS m/e 184.8 1H-NMR (CDCl3) δ ppm: 0.08 (s, 6H, CH3) 0.9 (s, 9H,
CH3), 1.95 (t, 1H, CH), 2.40 (m, 2H, CH2), 3.74 (t, 2H, CH2).
4-(tert-butyldimethylsiloxy) 1, 2 o-carborane (4.6): Decarborane (1.328 gm, 10.86
mmol), diethyl sulfide (2.236 gm, 24.8 mmol) and toluene (25 ml) were combined in a
schlenk tube equipped with the stirbar. The solution was maintained at 40 0C for 3 hours
and then at 60 0C for 2 hours and finally was cooled to room temperature. 4-(tertbutyldimethylsiloxy) 1-butyne 4.5 (2 gm, 10.86 mmol) dissolved in the minimum amount
of toluene was added to B10H12. 2S(CH2CH3) in the schlenk tube under argon
atmosphere. The reaction was slowly warmed to 80 0C and stirred for 3 days .The
solution was cooled and stripped of the solvent on a rotary evaporator to get an a oily
compound. 250 ml of methanol was added to this oily compound and refluxed to destroy
any unreacted boranes and then ethanol was added to remove the excess diethylsulfide by
co-distillation. The residue was washed with water and organic extract was dried over
Na2SO4.The crude material was purified on a silica column (EtOAc: hexane- 1:9) to get
the product in 60% yield (2.0 gm). MS m/e 303.46; 1H-NMR (CDCl3) δ ppm: 0.06 (s,
6H, CH3) 0.9 (s, 9H, CH3), 2.44 (t, 2H, CH2), 3.72 (t, 2H, CH2) 4.01 (s, 1H, CH).
[4-(1-tert-butyldimethylsiloxyethylene)-o-carboranyl)methyl]bromobenzene (4.7) :
n-BuLi (0.660 ml, 1.6 M in hexane) was added dropwise to a solution of 4-(tertbutyldimethylsiloxy) 1, 2 o-carborane 4.6 (0.240g, 0.790 mmol) in dry THF (10 ml), at a
temperature between -5o and 0o C, under Argon. The mixture was stirred at this
temperature range for one and a half hours, then cooled to -15o to -20o C (ice/salt bath). A
solution of LiI (0.034 g, 0.246 mmol) in dry THF (2 ml) and 4-bromomethyl
bromobenzene (0.196 g, 0.781 mmol) in THF (1 ml) was added and the final reaction
mixture allowed to warm up to room temperature and stirred for 16 hours. After
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quenching the reaction with water the resulting mixture was extracted four times with
diethyl ether. The organic extracts were washed once with water, once with brine, dried
over anhydrous Na2SO4 and the solvent removed under vacuum. The crude product was
purified by column chromatography using dichloromethane/hexane 6:4 for elution, and
the main product collected to give 0.180 (56% yield) of the title compound,. MS m/e
497.3; 1H-NMR (CDCl3) δ ppm: 0.08 (s, 6H, CH3) 0.90 (s, 9H, CH3), 2.56 (t, 2H, CH2),
3.48 (s, 2H, CH2), 3.82 (t, 2H, CH2), 7.05(d, 2H, Ar-H), 7.47 (d, 2H, Ar-H).
4-(bromomethyl)bezaldehyde(4.12): 4-(bromomethyl)cyanobenzene 4.11 (1.84 gm, 10
mmol) was dissolved in 50 ml of dry toluene and argon was bubbled through the solution
for 30 minutes. DIBAL-H(10 ml, 10mmol) was then added at 0oC dropwise. After
addition, the reaction mixture was heated at 55oC for 1 day .Then 10% H2SO4 was added
until pH< 4. The resulting reaction mixture was stirred at room temperature overnight
before being worked-up. The reaction mixture was separated and the aqueous phase was
extracted with toluene. The combined organic phase was washed with water several
times, before removing the solvent on a rotary evaporator. A yellowish solid was
obtained. The title compound was recrystallized from CH2Cl2/hexane to give a white
crystalline solid (1.8 gm, 90% yield).1H-NMR (CDCl3) δ ppm: 4.52 (s, 2H, CH2), 7.54 (d,
2H, Ar-H), 7.85(d, 2H, Ar-H), 10.02(s, 1H, CHO).
4-(bromomethyl)benzenedithiane (4.13): Boron trifluoride di ethyl etherate (0.014 gm
,0.1 mmol) was added to solution of 4-(bromomethyl)benzaldehyde 4.12 ( 0.199 gm ,1.0
mmol) and ethane dithiol (0.103 gm, 1.1 mmol) at 0 0C under argon. After 10 min the
reaction mixture was first washed with 10% NaOH and then with saturated NaCl .The
organic extract was dried over Na2SO4. A white solid was obtained on evaporation of
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solvent in 0.175gm (63% yield). 1H-NMR (CDCl3) δ ppm: 3.36(m, 4H, CH2), 3.52(s, 2H,
CH2), 5.62(s, 1H, CH), 7.32(d, 2H, Ar-H), 7.48(d, 2H, Ar-H).
[4-(1-tert-butyldimethylsiloxyethylene)-o-carboranyl)methyl]benzenedithiane (4.14):
n-BuLi (0.445 ml, 1.6 M in hexane) was added dropwise to a solution of 4-(tertbutyldimethylsiloxy) 1,2 o-carborane 4.6 (0.162 g, 0.533 mmol) in dry THF (5.0 ml), at a
temperature between -5o and 0o C, under Argon. The mixture was stirred at this
temperature range for one and a half hours, then cooled to -15o to -20o C (ice/salt bath). A
solution of LiI (0.023 g, 0.165 mmol) in dry THF (2 ml) and compound 4.13 (0.145 g,
0.527 mmol) in THF (1 ml) was added and the final reaction mixture allowed to warm up
to room temperature and stirred for 16 hours. After quenching the reaction with water the
resulting mixture was extracted four times with diethyl ether. The organic extracts were
washed once with water, once with brine, dried over anhydrous Na2SO4 and the solvent
removed under vacuum. The crude product was purified by column chromatography
using dichloromethane/hexane 6:4 for elution, and the main product collected to give
0.125 (48% yield) of the title compound. MS m/e 497.3; 1H-NMR (CDCl3) δ ppm: 0.08
(s,6H, CH3) 0.91 (s, 9H, CH3), 2.57 (t, 2H, CH2), 3.36 (m, 2H, CH2), 3.49 (s, 2H, CH2),
3.52 (m, 2H, CH2), 3.82 (t, 2H, CH2), 5.63 (s, 1H, CH), 7.12 (d, 2H, Ar-H), 7.50 (d, 2H,
Ar-H).
[4-(1-tert-butyldimethylsiloxyethylene)-o-carboranyl)methyl]benzaldehyde

(4.10):

compound 4.14 (0.050 gm, 0.1006 mmol) is dissolved in 5% aqueous THF(3 ml) in a
RBF equipped with a stirrer under argon. To this reaction mixture a solution of mercury
(II) perchlorate (0.080 gm, 0.200 mmol) was added drop-wise and the final reaction was
stirred at room temperature for 15 min .The reaction mixture was filtered and the filtrate
was extracted with diethyl ether. The organic phase was washed with saturated solution
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of Na2CO3,then with water and finally dried over Na2SO4.The crude product was
concentrated and purified by column chromatography (silica gel, EtOAc/Hexane-1:9) to
give a pure product in 65% yield (0.030 gm). Theoretical mass: 422.3; 1H-NMR (CDCl3)
δ ppm: 0.10 (s, 6H, CH3) 0.91 (s, 9H, CH3), 2.59 (t, 2H, CH2), 3.61 (s, 2H, CH2), 3.84 (t,
2H, CH2), 7.36 (d, 2H, Ar-H), 7.86 (d, 2H, Ar-H), 10.03 (s, 1H, CHO).
Tri(ethyleneglycol)monomethylethertosylate(4.17): Tosylchloride (10.5 gm, 55mmol)
was added in portions into a solution of tri(ethylenegycol)monomethylether (8.2 gm, 50
mmol) in anhydrous pyridine ( 50 ml). This reaction mixture was cooled to 0oC and
stirred overnight. The reaction mixture was then poured on crushed ice and extracted with
ethyl ether. The organic phase was washed with 1mol/lit HCl and water and then dried
over Na2SO4. It was then evaporated under vacuum to yield pale yellow liquid in 5.5 gm
yield. This was proceeded to next step without purification.
Tri(ethyleneglycol)monomethyl Iodide(4.18): A mixture of Tri(ethyleneglycol)
monomethyltosylate 4.17 ( 5.5 gm, 17.3 mmol), sodiumiodide ( 5.19 gm, 34.6 mmol) and
butanone ( 32 ml) were refluxed for 2 h. water was then added to the partially evaporated
reaction mixture and then the mixture was extracted with ethyl ether. The organic phase
was washed with NaHSO3 solution and water; it was dried over Na2SO4 and evaporated
to give product as a pale yellow liquid. It was purified with 10:1(DCM: ethylacetate) to
get 4.3 gm (92% yield). Mass: 274.01; 1H-NMR (CDCl3) δ ppm: 3.27 (m, 2H, CH2), 3.40
(s, 3H, CH3), 3.57 (m, 2H, CH2), 3.66 (m, 6H, CH2), 3.77 (m, 2H, CH2).
p-Ethynylbenzyl(1,3-dithiane) (4.20): To a solution of 4-ethynylbenzaldehyde 4.19 (6.0
g, 46.15 mmol) and 1,2-ethanedithiol (5.0 g, 53.09 mmol) was added BF3·OEt2 (0.654 g,
4.62 mmol) at 0 0C under argon. The mixture was stirred at 25 0C for 15 m then washed
once with a 10% aqueous NaOH solution, and once with aqueous saturated solution of
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NaCl. The organic layer was dried over anhydrous Na2SO4 and the solvent removed
under vacuum. The resulting residue was purified by column chromatography
(dichloromethane-hexane, 1:4) to give 7. 0 g (80%) of p-ethynylbenzyl(1,3–dithiane).
M.p: 68-69 oC; MS (EI) m/z 206.0 (M+); 1H-NMR (CDCl3) δ ppm: 3.09 (s, 1H, CH),
3.38 and 3.52 (m, 2H each, CH2CH2), 5.62 (s, 1H, SCH), 7.42 (d, 2H, Ar-H,), 7.48(d, 2H,
Ar-H).
p-(o-Carboranyl)benzyl(1,3-dithiane) (4.21): A solution of decacarborane (3.0 g, 24.59
m mol) and ethyl sulfide (5.0 g, 55.44 mmol) in dry toluene (50 ml) were combined in a
schlenk tube and was heated at 40 0C for 3 h and then at 60 0C for 2 h. The solution was
allowed to cool to 25 oC and to this mixture p-ethynylbenzyl(1,3-dithiane) 4.20 (5.0g,
24.26 mmol) in dry toluene (10 ml) was added and the final mixture was stirred at 80 0C
for 3 days. After cooling to room temperature, the mixture was concentrated under
vacuum and the oily residue was dissolved in methanol (250 ml) and heated to reflux for
1 h (until no hydrogen was liberated). At room temperature, 2.5 ml of HCl (50%
aqueous) was added dropwise and the mixture was again refluxed for another 30 m until
the evolution of hydrogen was complete. After cooling to 25 0C, the mixture was diluted
with ethanol and excess ethylsulfide was removed by ethanol-ethylsulfide co-distillation.
The resulting residue was reduced in volume under vacuum and dissolved in 100 ml of
benzene (CAUTION) at 5 0C. This was followed by addition of 100 ml of cold 10%
aqueous NaOH solution, and the mixture was allowed to stir vigorously for 15 m. The
organic layer was separated and washed twice with water and dried over anhydrous
Na2SO4. After removing the solvent under vacuum, the residue was purified by column
chromatography (eluting with dichloromethane-hexane, 1:4) to give 5.2 g (67%) of the
title compound. M.p: 118-119 0C; MS (EI) m/z 324.1 (M+); 1H-NMR (CDCl3) δ ppm: 1.6
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- 3.3 (br, 10H, BH), 3.36 and 3.47 (m, 2H each, CH2CH2), 3.94 (br s, 1H, o-carboraneCH), 5.59 (s, 1H, SCH), 7.40 (d, 2H, Ar-H), 7.46 (d, 2H, Ar-H).
1-[3’, 6’, 9’-Trioxadecyl)-1, 2-dicarba-closo-dodecaborane (4.25): A two necked
round bottom flask with o-carborane (0.288 gm, 2 mmol) dissolved in dry THF ( 20 ml)
under argon was stirred at -780C for 1h. To this mixture n-BuLi (1.3 ml, 1.6 M in hexane)
was

added

dropwise

and

stirred

for

1h

at

-780C.

After

which

Tri(ethyleneglycol)monomethylIodide 4.18 (0.548 gm, 2 mmol) in dry THF was added
drop wise and stirred for 2 h at -780C and then slowly warmed to room temperature and
stirred overnight. The final reaction mixture was neutralized with H2O, separated with
ethyl acetate and washed with water and brine. It was then dried over anhydrous Na2SO4
and separated on silica gel column (1:3, EtoAc: hexane) to yield 0.300 gm (52 % yield).
Mass: 290; 1H-NMR (CDCl3) δ ppm: 1.00-3.42 (m, 10H, B-H), 2.55 (t, 2H, CH2), 3.41
(s, 3H, CH3), 3.56-3.66 (m, 10H, CH2), 4.25 (s, 1H, CH).
1-[3’, 6’, 9’-Trioxadecyl)-1, 2-dicarba-closo-dodecaborane (4.25): A two necked
round bottom flask with O-carborane (0.864 gm, 6 mmol) dissolved in dry THF ( 60 ml)
under argon was stirred at 00C for 0.5 h. To this mixture n-BuLi (4 ml, 1.6 M in hexane)
was

added

drop

wise

and

stirred

for

1.5

h

at

00C.

After

which

Tri(ethyleneglycol)monomethyltosylate 4.17 (1.90 gm, 6 mmol) in dry THF was added
drop wise and then slowly warmed to room temperature and stirred overnight. The final
reaction mixture was neutralized with H2O, separated with ethyl acetate and washed with
NaHSO3, water and brine. It was then dried over anhydrous Na2SO4 and separated on
silica gel column using DCM to yield 1.0 gm (60 % yield). Mass: 290; 1H-NMR (CDCl3)
δ ppm: 2.55 (t, 2H, CH2), 3.41 (s, 3H, CH3), 3.56-3.66 (m, 10H, CH2), 4.25 (s, 1H, CH).
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N-Propargyl phthlamide (4.32): To a suspended solution of potassium phtlamide (5.00
g, 26.993 mmol) in acetone (100 ml) was added propargyl bromide 4.31 (5 ml of 80%
solution in toluene). The mixture was refluxed for 12 hrs and filtered. The acetone was
removed and the residue was purified by column chromatography (silica gel, chloroform:
petroleum ether-90:10) to give 4 gm of the product (80 % yield) MS m/e 185.19; 1HNMR (CDCl3) δ ppm: 2.23(s, 1H, CH), 4.46(s, 2H, CH2), 7.75(d, 2H, Ar-H), 7.87(d, 2H,
Ar-H).
4-(phthlamidopropnyl)-benzaldehyde (4.33): To a solution of 4-bromobenzaldehyde
(5.00 g, 27.04 mmol) and triphenyl phosphine (0.350 g, 1.336 mmol) in anhydrous
triethyl amine (50 ml) under argon, were added N-Propargylphthlamide 4.32 (6.26 gm,
33.8 mmol) in toluene and palladium (II) acetate (75 mg, 0.334 mmol).The final mixture
was heated to reflux for 8 hours and then cooled to room temperature and it was then
filtered. The filtrate was concentrated and purified by column chromotography (silica gel,
CH2Cl2: petroleum ether- 1:4) to give the resultant compound in 78% yield (6.12 gm).
MS m/e 289.29; 1H-NMR (CDCl3) δ ppm: 4.71(s, 2H, CH2), 7.26(d, 2H, Ar-H), 7.58(d,
2H, Ar-H), 7.77(d, 2H, Ar-H), 7.90(d, 2H, Ar-H), 9.98(s, 1H, CHO).
4-(phthlamidopropnyl)-phenyl 1, 2-dithiane (4.34): Boron trifluoride diethyl etherate
(0.306 gm, 2.16 mmol) was added to solution of 4-(phthlamidopropnyl)-benzaldehyde
4.33 (5 gm, 17.28 mmol) and ethanedithiol (2.03 gm, 21.60 mmol) at 0 0C under argon.
After 10 min the reaction mixture was first washed with 10% NaOH and then with
saturated NaCl. The organic extract was dried over Na2SO4. A dark yellow oil obtained
on evaporation of solvent was purified by chromatography (silica, CH2Cl2: pet-ether- 1:4)
yield a white solid in 5.30 gm (83% yield). MS m/e 365.46; 1H-NMR (CDCl3) δ ppm:
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3.36(m, 4H, CH2), 4.68(s, 2H, CH2), 5.59(s, 1H, CH), 7.37(d, 2H, Ar-H), 7.45(d, 2H, ArH), 7.77(m, 2H, Ar-H), 7.90(m, 2H, Ar-H).
4-(1-methylphthlamidocarborane)-phenyl 1, 2-dithiane (4.35): Decarborane (0.700
mg, 5.7377 mmol), diethyl sulfide (1.046 gm, 11.6 mmol) and toluene (50 ml) were
combined in a schlenk tube equipped with the stir bar. The solution was maintained at 40
0

C for 3 hours and then at 60 0C for 2 hours and finally was cooled to room temperature.

4-(phthlamidopropnyl)-phenyl 1, 2-dithiane 4.34 (2 gm, 5.47 mmol) dissolved in the
minimum amount of toluene was added to B10H12.2S (CH2CH3) in the schlenk tube under
argon atmosphere. The reaction was slowly warmed to 80 0C and stirred for 3 days .The
solution was cooled and stripped on a rotary evaporator to get an a oily compound. 250
ml of methanol was added to this oily compound and refluxed to destroy any unreacted
boranes and then ethanol was added to remove the excess diethylsulfide by codistillation. The residue was washed with water and organic extract was dried over
Na2SO4.The crude material was purified on a silica column (CH2Cl2: hexane- 4:1) to get
the product in 60% yield (400 mg). MS m/e 484.46; 1H-NMR (CDCl3) δ ppm: 1.9-3.3
(br, 10H, B-H), 3.50(m, 4H, CH2), 3.90(s, 2H, CH2), 5.62(s, 1H, CH), 7.59(d, 2H, Ar-H),
7.70(d, 2H, Ar-H), 7.77(m, 2H, Ar-H), 7.88(m, 2H, Ar-H).
4-(1-methylphthlamidocarborane)-benzaldehyde (4.36): The compound 4.35 (400 mg,
0.826 mmol) was dissolved in 5 ml of THF (5 % aqueous) in a 2-neck RBF under argon.
To this a solution of mercury (II) perchlorate (660 mg, 1.652 mmol) in THF was added
drop wise. The mixture was stirred for 15 min at room temperature. The reaction mixture
was filtered and the filtrate was extracted with diethyl ether. The organic phase was
washed with saturated solution of Na2CO3 and with water and finally dried over
Na2SO4.The crude product was purified by column chromatogaphy to get pure product in
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75% yield. MS m/e 484.46; 1H-NMR (CDCl3) δ ppm: 1.9-3.3 (br, 10H, B-H), 3.90(s, 2H,
CH2), 7.59(d, 2H, Ar-H), 7.70(d, 2H, Ar-H), 7.77(m, 2H, Ar-H), 7.88(m, 2H, Ar-H),
10.02 (s, 1H, CHO).
Meso-tetra[4-(1-methylphthlamido-carborane)phenyl]porphyrin (4.37): A solution
of the aldehyde 4.36 (0.420 g, 1.031 mmol) and freshly distilled pyrrole (0.078 ml,1.135
mmol) in dry CH2Cl2 (100 ml) was purged with argon for 15 min. TFA (0.040 ml, 0.5155
mmol) was added to the solution and the mixture was stirred at the room temperature
under argon for 2.5 h (complete disappearance of starting compound monitored by TLC
). After addition of p-chloranil (0.190 g, 0.773 mmol) the reaction mixture was stirred at
room temperature for 2 h. The solution was then washed once with aqueous saturated
NaHCO3, and once with water before being dried over anhydrous Na2SO4. The residue
obtained after removal of the solvent under vaccum was purified by the column
chromatography on the silica gel (CH2Cl2/Hexane 7:3) 0.005 g of the title compound as
purple crystals. Calculated weight 1822.32(M+). UV-Vis (CHCl3) λmax 421 nm, 515 nm,
550 nm, 585 nm, 645 nm.
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Chapter 5
Synthesis of a Carboranylsapphyrin
5.1 Introduction
Sapphyrins are an important group of expanded porphyrins with an additional pyrrole
subunit introduced into the porphyrin macrocycle. A sapphyrin macrocycle consists of
five pyrrole rings linked by four methine bridges and one direct pyrrole-pyrrole bond.
The sapphyrins are aromatic, like porphyrins and corroles, with an aromatic 22 electron π
system which is confirmed by a Soret band at 450 nm in the UV-visible spectrum and
diamagnetic ring current effects in the 1H NMR spectrum. The sapphyrins allow the study
of aromaticity in large conjugated systems, and they also have the practical importance of
the expanded core which can coordinate large metal ions.1 The sapphyrin shows more
basicity than the porphyrin macrocycle and it can be easily obtained as the dication after
chromatography on silica gel. The monocation and the freebase sapphyrins can be
obtained by the controlled addition of bases to the dication.2
Sapphyrins were the first expanded porphyrin to be obtained accidentally by R. B.
Woodward and coworkers during their earlier attempts to synthesize the corrin core of
vitamin B12.3 Woodward and coworkers implemented the most commonly used synthesis
of sapphyrin 5.3 by a (3+2) approach (Scheme 5-1) where a bipyrrole aldehyde 5.1 was
condensed with tripyrrane 5.2.4,
efficient

synthetic

route

5

Woodward and coworkers also developed a less

involving

a

(4+1)

condensation

(Scheme

5-2)

of

bipyrryldipyrromethane 5.4 and pyrrole dialdehyde 5.5.3 The one pot synthesis of
sapphyrins was found by Woodward and Sessler groups.6,

7

Latos-Grazynski and

coworkers developed an easy one-pot synthesis of sapphyrin by condensation of
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benzaldehyde and pyrrole in a 1:3 molar ratio under conditions of oxidative acid
catalysis.8
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Scheme 5-1: Synthesis of sapphyrin 5.3 using a (3+2) approach by Woodward and
coworkers4
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Scheme 5-2: Synthesis of sapphyrin 5.6 using a (4+1) approach by Woodward and
coworkers3
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They reported very low yields of 1%. Dolphin and coworkers reported reasonable yields
for the efficient synthesis of sapphyrins using tripyrrane precursors.9 Tavarekere and
coworkers developed a one-pot synthesis of sapphyrins from a dipyrromethane with
yields of 7%.10 A high yield (20% yield) method for the synthesis of the sapphyrin was
developed by Paolesse, Smith and coworkers.11 This method involves the formation of
sapphyrin 5.9 (Scheme 5-3) from biladiene 5.7 and formylpyrrole 5.8.
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Scheme 5-3: Synthesis of sapphyrin 5.9 from biladiene 5.7 and formylpyrrole 5.8 by
Paolesse, Smith and coworkers11
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The method also enables preparation of sapphyrins with substituents arranged in a less
symmetrical fashion than those obtained using the other methods.
The UV-Visible spectra of sapphyrins show an intense Soret band at around 456 nm
indicating a polypyrrolic aromatic macrocycle and this is accompanied by weak Q type
absorption bands between 616 and 790 nm.12,

13, 14

The sapphyrin also exhibits

flourescence properties upon excitation within the Soret band. The 1H-NMR of the
unsymmetrical sapphyrins is strongly dependent upon the pattern of the peripheral
substituents and the nature of the counter ion.4 The 1H-NMR of the sapphyrins are similar
to that of the porphyrins with the external meso-type protons reasonating around 10 ppm
and the internal NH protons located around -2 ppm. Sapphyrins have a larger core size
than the porphyrin (an internal N-N distance of about 5.5 A0 compared to 4.0 A0).
Because of this and the presence of an additional nitrogen donor site, the sapphyrins
might stabilize large metal complexes.15 Woodward and coworkers reported the
formation of the Zn and Co complexes and the Sessler group reported the Rh and Ir
complexes with the metal ion located outside the plane of the macrocycle.16 In 1990, the
first X-ray crystallographic analysis of a sapphyrin derivative, showing a planar
diprotonated sapphyrin with five hydrogen bonds to a central fluoride anion, led to the
suggestion that sapphyrins may act as anion receptors. 17-20 A great deal of work has been
done in the area of anion binding and transport properties of sapphyrin.21,

22, 23

Diprotonated sapphyrins have potential as receptors of biologically important anions,
such as phosphates, including nucleotide monophosphate.12, 13, 14 A single oxygen of the
phosphate is displaced from the five nitrogen plane and forms the hydrogen bonds with
some of the NH protons of the diprotonated sapphyrin. These numbers of hydrogen bonds
to the oxygen distinguishes the phosphate unit.24, 25 The binding of halide ions, 26, 27, 28
157

azide29,

30

and carboxylate31,

32

was also explored. Sapphyrins are also known to be

solution-phase carriers for nucleotides,33 nucleotide analogues21 and amino acids.34
Sapphyrins have potential application in PDT because of their absorbance in the 680-710
range of the spectral region.4, 26, 27, 35 This property is an important prerequisite for a new
generation of photosensitizers which can achieve a greater depth of light penetration.
In this chapter I report the first synthesis of a carboranylsapphyrin. The
carboranylsapphyrin was synthesized in very low yield and consequently its
characterization was not complete. The goal of this project was to make a novel
tetracarboranylsapphyrin followed by insertion of gadolinium into the sapphyrin core.
This would make it an ideal NCT agent as both the 10B and the
neutrons and result in NCT.
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Gd would capture the

Gd has a higher cross section of neutron capture than the

boron.36
5.2 Synthesis of a Carboranylsapphyrin
The synthesis of a carboranylsapphyrin happened by accident during the synthesis of
meso-tetra(3-carboranylphenyl)porphyrin. The meso-tetra(3-carboranylphenyl)porphyrin
was being synthesized in order to study its biological properties in comparison with the
isomeric meso-tetra(4-carboranylphenyl)porphyrin which has the carborane groups on the
para-

rather

than

the

meta-positions.

The

synthesis

of

meso-tetra(3

carboranylphenyl)porphyrin started with 3-carboranylbenzaldehyde 5.10, as seen in
Scheme 5-4. The benzaldehyde 5.10 was condensed with freshly distilled pyrrole in the
presence of TFA.37 After the formation of the porphyrinogen it was oxidized with pchloranil to form the meso-tetra(3-carboranylphenyl)porphyrin 5.11. But when the
separation was performed using 2:3 ratio of CH2Cl2 and hexane on a silica gel column,
three different products were obtained.
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Scheme 5-4: Synthesis of sapphyrin 5.12, corrole 5.13 and porphyrin 5.11
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The fastest running fraction contained both sapphyrin 5.12 and the porphyrin 5.11 and
this was followed by a fraction with the corrole 5.13. The fast running fraction with the
sapphyrin 5.12 and the porphyrin 5.11 was further separated using 4.5:5.5 ratio of DCM
and hexane on a silica gel column. Sapphyrin 5.12, corrole 5.13 and porphyrin 5.11 were
all characterized by MALDI-MS, UV-Vis, 1H-NMR. This unexpected formation of
sapphyrin sparked the idea to make the carboranylsapphyrin in larger amount, followed
by gadolinium ion insertion in its inner core which would make it an ideal gadolinium
and boron NCT agent. Gadolinium has the highest neutron capture cross section value
which is 66 times more than that of

10

B and with the presence of boron will make it a

perfect BNCT delivery agent if it can selectively localize in the tumor cells. Following a
similar

synthetic

scheme

carboranylphenyl)sapphyrin

as

for

5.12,

the
the

synthesis
synthesis

of

the

meso-tetra(3-

of

a

meso-tetra(4-

carboranylphenyl)sapphyrin 5.16 was tried using as the starting material 4-carboranyl
benzaldehyde 5.14 because of its easy availability of compared with the 3-carboranyl
benzaldehyde 5.10.
The synthesis of meso-tetra(4-carboranylphenyl)sapphyrin 5.16 was initially attempted
using the method devised by Tavarekere and coworkers10 and then the one-pot synthesis
by the Latos-Grazynski was also tried.8
A one-step synthesis of sapphyrin 5.16 was attempted using a condensation of meso(4carboranylphenyl)dipyrromethane 5.15 with the benzaldehyde 5.14, as seen in Scheme 55.

The

meso-carboranyldipyrromethane

5.15

was

synthesized

from

4-

carboranylbenzadehyde 5.14 and freshly distilled pyrrole. The 4-carboranylbenzaldehyde
5.14 was dissolved in 34 equivalents of pyrrole and a drop of TFA was added. The final
mixture was stirred at room temperature for 20 min. The excess pyrrole was distilled to
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give the dipyrromethane product 5.15 in 90% yield. Dipyrromethane 5.15 was
characterized with 1H-NMR as seen in Figure 5-1. Dipyrromethane 5.15 was used for the
one-pot synthesis of sapphyrin 5.16 by a route suggested by Tavarekere and coworkers.10

CHO

Pyrrole

H
TFA
DCM
p-chloranil

TFA
H

NH
5.14

H

HN

5.15

N
H

N

N
NH

H

H
N

H

H

= BH
=C
5.16

Scheme 5-5: Synthesis of the sapphyrin 5.16 from dipyrromethane 5.15

The dipyrromethane 5.15 was dissolved in dry DCM and to this solution one equivalent
of TFA was added. After stirring for one hour p-chloranil was added. A black
polymerized mixture was obtained which was very hard to separate.
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Figure 5-1: 1H-NMR of the dipyrromethane 5.15 in CDCl3 at 300 MHz

None of the fractions could be separated in pure form for characterization. This route was
not repeated anymore because of the uncertainty in the conversion of the dipyrromethane
into a sapphyrin. The 4-carboranylbenzaldehyde 5.14 used is also difficult to synthesize
and with the addition of the uncertain results this method was abandoned.
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Another one pot methodology suggested by Latos-Grazynski and coworkers was
attempted. In this synthesis of sapphyrin was prepared from benzaldehyde 5.17 instead of
4-carboranylbenzaldehyde 5.14 in order to test the conditions for this route. The reaction
of benzaldehyde 5.17 with the excess pyrrole 5.18 (1:3 molar ratio) in dichloromethane
was done using BF3.Et2O as a catalyst (Scheme 5-6). The BF3.Et2O was used under
modified conditions as compared to those used in the synthesis of the porphyrins.

N
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N

+
1
5.17

:

N

BF3.OEt2
N
H

DCM
p-chloranil

NH

H
N

3
5.18

5.19

Scheme 5-6: Synthesis of sapphyrin 5.19 from benzaldehyde 5.17 and pyrrole 5.18

This reaction yielded a very low yield (1%) of the tetraphenylsapphyrin 5.19 which was
obtained after complicated separations. The majority of the product was the
tetraphenylporphyrin obtained in 25% yield. 3% of corrole was also isolated. The
sapphyrin was characterized by MALDI-MS as seen in Figure 5-2. The sapphyrin had a
complicated NMR. In the next experiment TFA was used instead of the BF3.Et2O and
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after overnight stirring, p-chloranil was added to yield a mixture of products. The mixture
was separated by passing through basic alumina with DCM as the eluent. This separation
was followed by another separation of the fast running products with 10:1 of DCM/CCl4
which resulted in the minor yields (1%) of the tetraphenylsapphyrin 5.19. The sapphyrin
was characterized by MALDI-MS, which showed the molecular ion (Figure 5-2) with a
peak at 677.

Figure 5-2: MALDI-MS of the tetraphenylsapphyrin 5.19
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Using the mechanism of Rothemund synthesis designed for the sapphyrins by LatosGrazynski and coworkers the 4-carboranylbenzaldehyde 5.14 was condensed with three
equivalents of pyrrole 5.18 in very dry DCM (Scheme 5-7). The BF3.Et2O was used as a
catalyst and after the disappearance of the 4-carboranylbenzaldehyde 5.14 by TLC in the
reaction mixture, p-chloranil was added and the mixture was purified using 2:3
DCM/CCl4 solvent mixture. Several fractions obtained were analysed by MALDI mass
spectrometry.

The

fast

running

fraction

showed

the

meso-tetra(4-

carboranylphenyl)sapphyrin 5.16 peak at 1249, as seen in Figure 5-3. This was the only
characterization that was possible for this sapphyrin 5.16 as the amount of sapphyrin 5.16
obtained was very small.
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Scheme 5-7: Synthesis of the sapphyrin 5.16 from benzaldehyde 5.14 and pyrrole 5.18
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Figure 5-3: MALDI-MS of the tetracarboranylsapphyrin 5.16

The mechanism for the formation of the tetraphenylsapphyrin from the benzaldehyde and
pyrrole was proposed by Latos-Grazynski and coworkers.8 According to this mechanism
excess pyrrole molecules attack the tetrapyrromethane in its preferred helical
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conformation to create a helical pentapyrrolic structure. A significant distortion from the
planarity allows the extension of the structure by avoiding the overlap of the terminal
ligand substituents. The helical geometry of the pentapyrrole provides the required
orientation for the ring closure by the acidic α-α pyrrole coupling. This ring closing
results in a sapphyrinogen related molecule which can then be oxidized to sapphyrin.
All the methods utilized resulted in very low yields of the target sapphyrins, less than 1%.
The most plausible route which can deliver high yields of sapphyrins for further
metalation with gadolinium is yet to be done. This synthesis of the sapphyrin can be
followed by the evaluation of its in vitro and the in vivo characteristics. The most
promising route for the synthesis of the meso substituted tetracarboranylsapphyrin 5.16
might be the one proposed by Dolphin and co-workers.9 This route follows a 3+2
condensation of tripyrrane 5.21 and bipyrrole 5.20 to form the tetracarboranylsapphyrin
5.16. Dolphin and coworkers formed a tripyrrane as a side product in a single step
reaction by condensation of excess pyrrole with benzaldehyde in presence of the acid.
The tripyrrane was obtained as a red-orange glass after the sublimation of the crude
products. Tripyrranes have been previously synthesized by multi-step procedures by Lee
and coworkers.38 5, 10-Di(4-carboranyl)phenyltripyrrane 5.21 could be obtained using a
similar procedure to that of Dolphin and coworkers, as it would minimize the number of
steps. Tripyrrane 5.21, dipyrrole 5.20 and the 4-carboranylbezaldehyde 5.14 can be
dissolved in dry DCM (Scheme 5-8). This can be followed by the condensation with
BF3.Et2O to form the macrocycle which can then be aromatized with p-chloranil. The
target tetracarboranylsapphyrin 5.16 once obtained can be metalated with gadolinium to
form the metalated tetracarboranylsapphyrin 5.22.
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Scheme 5-8: Proposed synthesis of the metalated sapphyrin 5.22
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5.3 Conclusions
The synthesis of the tetraphenylsapphyrin 5.19 and the tetracarboranylsapphyrin 5.16 was
achieved in very low yields. Many different routes for the synthesis of the
tetracarboranylsapphyrin 5.16 were tried with little success. Characterization of the
tetraphenylsapphyrin 5.19 and the tetracarboranylsapphyrin 5.16 was done by MALDIMS and UV-Vis. The synthesis of the target tetracarboranylsapphyrin 5.16 using the
synthetic route developed by Dolphin and coworkers will be tried. This route may result
in higher yields and further characterization of the tetracarboranylsapphyrin 5.16. This
sapphyrin would then be metalated with gadolinium and evaluated in vitro and in vivo for
application in gadolinium and boron neutron capture therapy.
5.4 Experimentals
Chemistry: Commercially available starting materials were purchased from SigmaAldrich and used without further purification. All solvents were purchased from Fisher
Scientific (HPLC grade) and either directly used or dried and distilled according to
literature procedures. Silica gel 60 (70-230 mesh, Merck) and alumina grade III (70-230
mesh ASTM) were used for column chromatography. Analytical thin-layer
chromatography (TLC) was performed on Merck 60 F254 silica gel (precoated sheets, 0.2
mm thick). 1H-NMR spectra were obtained using a Bruker DPX 250 MHz or 300 MHz
spectrometer; chemical shifts are expressed in ppm relative to TMS (0 ppm). Electronic
absorption spectra were measured on a Perkin Elmer Lambda 35 UV-Vis
spectrophotometer and fluorescence spectra on a Perkin Elmer LS55 instrument. Low
resolution MS analyses were conducted at the LSU Mass Spectrometry Facility on a
Bruker Prolix III MALDI-TOF mass spectrometer, and the HRMS were conducted at the
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Ohio State University Mass Spectrometry and Proteomics Facility. Melting points were
measured on an Electrothermal MEL-TEMP instrument.
Meso-tetra(3-carboranylphenyl)sapphyrin

(5.12):

A

solution

of

the

3-

carboranylbenzaldehyde 5.10 (0.124 g, 0.5 mmol) and freshly distilled pyrrole (0.035
mL, 0.505 mmol) in dry CH2Cl2 (50 ml) was purged with argon for 15 min. TFA (0.020
ml, 0.25 mmol) was added to the solution and the mixture was stirred at the room
temperature under argon for 20 h (complete disappearance of starting

compound

monitored by TLC ). After addition of p-chloranil (0.093 g, 0.375 mmol) the reaction
mixture was stirred at room temperature for 2 h. The solution was then washed once with
aqueous saturated NaHCO3, and once with water before being dried over anhydrous
Na2SO4. The residue obtained after removal of the solvent under vaccum was purified by
the column chromatography on the silica gel (CH2Cl2/hexane .45:.55) and the fastest
running fraction was collected and recrystallized from CH2Cl2/methanol, yielding the title
compound, mp >300 0C . MS (MALDI) m/e 1249.365 (M+).
Meso(4-carboranylphenyl)dipyrromethane (5.15): 4-carboranylbenzaldehyde 5.14 (
0.124 gm, 0.5 mmol) was dissolved in the pyrrole ( 1.18 ml, 17 mmol) and was bubbled
with argon for 5 min. To this mixture a drop of TFA was added and stirred under argon
for 15-20 min. The final reaction mixture was quenched with water after the complete
consumption of the aldehyde and it was extracted with DCM. The organic fractions were
washed with water and dried over Na2SO4. Vacuum distillation was done to remove the
pyrrole and then it was purified by passing it through a silica gel column (3:7,
ethylacetate: hexane) to yield the pure compound in 90% yield. Mass: 364.

1

H-NMR

(CDCl3) δ ppm: 1.8 - 3.5 (br, 10H, BH), 3.96 (br s, 1H, o-carborane-CH), 5.34 (s, 1H,
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CH), 5.91 (s, 2H, CH), 6.20 (q, 2H, CH), 6.76 (q, 2H, CH) 7.20 (d, 2H, Ar-H), 7.44 (d,
2H, Ar-H), 7.97 (s, 2H, NH).
Meso-tetra(4-carboranylphenyl)sapphyrin (5.16): 4-carboranylbenzaldehyde 5.14
(0.124 gm, 0.5 mmol) was dissolved in dry DCM (65 ml) and bubbled with argon for 15
min. first a freshly distilled pyrrole ( 0.104 mL, 1.5 mmol) was added to this mixture and
then BF3.OEt2 (0.024 mL, 0.1875 mmol) was also added. The reaction mixture was
stirred at room temperature overnight and then p-chloranil (0.125 gm, 0.187 mmol) was
added and stirred again for 3h. The solution was then washed once with aqueous
saturated NaHCO3, and once with water before being dried over anhydrous Na2SO4. The
residue obtained after removal of the solvent under vaccum was purified by the column
chromatography on the silica gel (CH2Cl2/CCl4, 2:3). A very small fraction of product
was obtained and was characterized with MALDI and UV-visible. It had a complicated
NMR. MS (MALDI) m/e 1249.755 (M+).
5, 10, 15, 20-tetraphenylsapphyrin (5.19): Benzaldehyde (0.807 mL, 8 mmol) was
added to a 1 L of DCM and bubbled with argon for 0.5 h and then pyrrole ( 1.662 mL, 24
mmol) and BF3.OEt2 (0.376 mL, 3 mmol) were added and stirred at room temperature
under argon for 2h. This was followed by oxidation with p-chloranil (2g) and stirred for
2h at the room temperature. The solution was evaporated to dryness and then passed
through basic alumina with DCM as solvent for elution. The fractions were collected and
then the solvent was stripped and passed through another column with 10:1 DCM: CCl4
to get a very small fraction of sapphyrin. MALDI confirmed the product 677.441
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